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Type II diabetes mellitus (TIIDM) causes multiple complications under chronic
hyperglycemia. Long term persistent exposure to elevated glucose conditions is considered
one of the major factors for diabetic complications. Pathologically, mechanical and
biochemical stimuli will induce a signaling cascade in cardiac fibroblasts, causing
myocardial fibrosis and leading to ventricular stiffness. Non-enzymatically, high levels of
glucose can react with long-lived proteins, such as collagen to form advanced glycation
end-products (AGEs). AGEs have been shown to be associated with many of the diabetic
cardiovascular complications due to their interaction with the receptor for AGE (RAGE).
AGE/RAGE activation stimulates the secretion of growth factors, promotes increased
collagen production that leads to tissue fibrosis, and increased RAGE expression. The
purpose of this study is to identify the role for Rap1a in regulating fibrosis under TIIDM
conditions, as well as to offer insight into the AGE-RAGE signaling cascade definition for
cardiovascular extracellular matrix remodeling under TIIDM conditions. To test our
hypothesis, both loss-of-function and gain-of-function based experiments were performed
to manipulate Rap1a protein expression in AGE-RAGE mediated fibrosis. Also, we down-

regulated the activity of downstream molecules in the AGE-RAGE signaling cascade, such
as protein kinase C-ζ (PKC-ζ) and ERK1/2 by specific inhibitor treatments, to test their
positions in AGE-RAGE mediated fibrosis pathway. To perform our experiment in vivo,
we used high fat diet to feed Rap1a heterozygous mice in order to build a Rap1a
heterozygous diabetic animal model. Our results showed that Rap1a protein plays a key
role in AGE-RAGE signaling pathway under TIIDM, and changes in Rap1a activity altered
the signaling pathway. Also, we found that PKC-ζ is the upstream player relatively to
ERK1/2, and Rap1a is the upstream player for both PKC-ζ and ERK1/2. By understanding
the role Rap1a played in AGE-RAGE signaling cascade, a new molecular mechanism is
found possibly to reduce the cardiac fibrosis in TIIDM patients.
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CHAPTER I
LITERATURE REVIEW
Introduction
Diabetes mellitus is a group of metabolic diseases characterized by hyperglycemia
due to either insulin insufficiency or insulin resistance. According to the American
Diabetes Association website(ADA), with chronically high levels of blood glucose, most
diabetic patients will develop multiple diabetes-related complications, including heart
dysfunction, stroke, kidney failure, blindness, or lower limb amputation among others.
There were 29.1 million people in the U.S. diagnosed as diabetic in 2010, and the risk of
heart attack is 1.8 times higher among adults diagnosed with diabetes compared to those
without diabetes (Zhao, J., et al., 2014). To date, there has not been a drug or treatment
found to cure this disease. Therefore, diabetes mellitus is considered a non-curable,
threatening of life-quality disease due to its complications. Due to the increasing number
of diabetic patients, the prevention of diabetes-associated complications becomes one of
the primary targets for diabetic research.
There are two major types of diabetes mellitus, type I and type II diabetes, which
share common symptoms, such as polydipsia (constant thirst), polyphagia (constant
hunger), and polyuria (constant urination). In particular, type I diabetes results from insulin
deficiency due to insufficient insulin production by the pancreas to maintain the regular
blood glucose level. On the other hand, type II diabetes mellitus is a metabolic disorder
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caused by insulin resistance, which results in a loss of insulin responsiveness according to
the ADA website. The pancreas of a type II diabetic patient function as well as that of nondiabetic patient, but the level of circulating insulin in type II diabetes patients is much
higher, resulting in a condition termed hyperinsulinemia. Therefore, despite elevated
insulin levels, cells are not stimulated to uptake glucose, which results in high circulating
glucose levels but relatively low intracellular glucose levels (Zhao, J., et al., 2014).
Blood glucose regulation and insulin signaling are controlled by molecular
signaling cascades shown in Figure 1.1. Once activated, the intracellular glucose level
increases, and ATP production is enhanced. Initial stimulation triggers pancreatic beta cell
K+ channel closing, resulting in cell depolarization. Plasma membrane depolarization
causes voltage-gated Ca2+ channels to open, and the rising of Ca2+ levels trigger the
molecular pathway that regulate insulin secretion (Ashcroft, M., et al., 2005). The released
insulin is transported to multiple cells through the circulatory system where it will bind to
target cells that possess insulin receptors (IRs) on their cell membrane. Insulin-insulin
receptor (IR) binding stimulates IR dimerization and auto-phosphorylation, followed by
insulin receptor substrate-1 (IRS-1) phosphorylation. Phosphoinositide 3-kinase (PI3K
kinase) is activated by IRS-1 to convert phosphatidylinositol biphosphate (PIP2) into
phosphatidylinositol (3,4,5)-triphosphate (PIP3). Akt, recruited by PIP3, activates GLUT4
storage vesicles (GSV) to fuse with the plasma membrane to ‘release’ the glucose
transporter. The major function for GLUT4 is to transport glucose from the plasma into
cells passively via the blood glucose diffusion gradient being higher in the blood as
compared to low intracellular concentrations (Ehrhardt, A., et al., 2014). The glucose
transporter, GLUT4, is one of the key transporters involved in insulin-mediated glucose
2

regulation. Under low concentrations of circulating insulin, GLUT4 is stored in the GSV.
Once insulin is released and interacts with its receptor, GSVs are activated, delivered to
the cell membrane, fuse with the cell membrane, and place GLUT4 transports on the
plasma membrane to increase glucose uptake and decrease the circulating blood glucose
levels.

Figure 1.1 Insulin signaling pathway. Insulin binding to the insulin receptor stimulates
insulin receptor auto-phosphorylation, followed by insulin receptor substrate (IRS)
phosphorylation. PI3K kinase is activated by IRS converting PIP2 into PIP3. Akt is
recruited by PIP3 after being fully phosphorylated and is responsible for glucose storage
vesicle (GSV) activation. Once activated, GSV fuses with the plasma membrane leading
to the transportation of glucose transporter molecules onto the plasma membrane.
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In type II diabetic patients, insulin receptors lose their sensitivity for insulin and the
glucose regulation pathway is dramatically reduced. As a result, blood glucose levels are
recorded at pathologically high levels, which is termed hyperglycemia (Kanwar YS, et al.,
2008). In order to maintain an intracellular glucose equilibrium, most cell types are able to
decrease glucose uptake, such as muscle cells and adipose cells; however, cells like
endothelial cells and mesangial cells are damaged under chronic hyperglycemia conditions,
as these cells are unable to regulate glucose transport efficiently (Berghe, G., 2004). The
organs most affected by hyperglycemic conditions include the kidneys and heart (Bieke F,
2004). Hyperglycemia can cause both acute and long-term changes in cellular metabolism,
which will develop into diabetic complications (Cade, S., et al., 2008). The non-enzymatic
interaction of glucose with lipids and proteins is also enhanced under these conditions,
which will be explained in more detail in the sections to follow. The glycated end-products
formed under hyperglycemic conditions will function as ligands to induce long-term
complications, including cardiac hypertrophy and dysfunction (Ramasamy, R., et al., 2005).

Extracellular Matrix (ECM)
The extracellular matrix (ECM) is the major structural scaffold for all tissues. It has
a key structural and mechanical role by providing a cellular scaffold to support the tissue,
as well as a functional role to serve as the adhesive material among cells to connect them
into tissues and organs. Furthermore, the ECM facilitates cellular migration in the wound
healing process. Activated fibroblasts or myofibroblasts, which are responsible for ECM
synthesis, actively participate in the wound healing process by moving to the edge of a
wounded area, generate contractile forces to reduce the open area, and then replace needed
4

ECM proteins to re-establish tissue integrity (Corda S, 2000). Likewise, the ECM can
function as a ‘pool’ for growth factor storage. For example, proteoglycans are ECM
proteins that act as “fillers” that are covalently attached by polycarbonate chains to other
ECM proteins. They possess a net negative charge, which will trap positive ions and growth
factors within the ECM (Corda S, 2000). In this way, the ECM is capable of controlling
rapid growth factor-mediated activation without requiring any new growth factor synthesis.
Thus, the ECM plays a key role in transducing both mechanical and chemical signals to
cells (Corda, S., et al., 2000).
The main components of the extracellular matrix include two general parts: 1)
insoluble materials, which cannot be hydrolyzed or enzymatically broken down, and 2)
soluble materials, which can be easily hydrolyzed or enzymatically degraded. The
insoluble components include collagen and elastin macromolecules, while the soluble
portions are composed of proteoglycans, hyaluronans, and adhesive glycoprotein
macromolecules (Baum, J., & Duffy, H., 2011).
Collagen
Collagen, a triple helix polypeptide, is the major fibrous protein in the ECM.
Although collagen is secreted mainly by fibroblasts, all cells are capable of secreting these
ECM proteins (Bowers, SL., et al., 2009). During collagen maturation, in the cytoplasm,
the signal peptide is removed to form preprocollagen. Preprocollagen then undergoes
further modification in the ER/Golgi which includes hydroxylation, whereby ‘-OH’
functional groups are added onto either a proline or lysine residue to form ‘Gly-X-Y’
repeated units in procollagen (Bowers, SL., et al., 2009). The preprocollagen is, then,
assembled into procollagen strands with cross-bridges being formed with hydrogen and
5

disulfide bonds (Bowers, SL., et al., 2009). For further maturation, procollagen will form
a triple helical structure, which will be secreted out of the cell (Bowers, SL., et al., 2009).
In the interstitium, procollagen peptidases will remove the N-terminal and C-terminal ends
of procollagen molecules forming mature insoluble tropocollagen (Bowers, SL., et al.,
2009). Tropocollagen will spontaneously self-assemble to form collagen fibers (Bowers,
SL., et al., 2009). Lysyl oxidase will form stable intermolecular and intramolecular
covalent crosslinks on the lysine/hydroxylysine residues between and within tropocollagen
molecular strands (Burgess, M., et al., 1994). This stable crosslinking provides a tensile,
highly organized collagen fiber network (Burgess, M., et al., 1994). Furthermore, collagen
proteins will interact with carbon chains in molecules such as fatty acid and glucose to
form a more complex and high molecular weight proteoglycan (Burgess, M., et al., 1994).
These proteolgycans are more stable and comprise much of the ECM (Burgess, M., et al.,
1994). Also, ECM proteins can be calcified in order to form bones and teeth (Bowers, SL.,
et al., 2009).
Collagen is the most abundant connective component in animal bodies, and it
accounts for 25% to 35% of the whole body protein (Sherman, V., 2015). Collagen is
primarily found in fibrous tissues, like tendons, ligaments, heart, bone, and skin. There are
many different collagen types found throughout the body; however, the top five prominent
collagen types will be discussed. Type I collagen is the most predominant collagen type
found in humans, and the other four prominent types include type II, III, IV and V
(Sherman, V., 2015). Type II collagen is the main component of cartilage (Sherman, V.,
2015). Type III collagen is a dense connective tissue component that is normally observed
to assemble with type I collagen (Sherman, V., 2015). Type IV collagen is responsible for
6

the basement membrane formation (Sherman, V., 2015). Type V collagen is most often
found within the epidermal junction, placental tissues, as well as in association with Type
I collagen (Sherman, V., 2015). Types I and III collagens are the main types of collagen
found in heart tissue, and these collagens maintain both the structural and functional
integrity of heart tissue (Sherman, V., 2015). Studies suggest that excess synthesis of type
I collagen is the primary cause of fibrosis-mediated myocardial hypertrophy
(Frangogiannis, G., 2012). Specifically, for cardiac tissues, type I collagen is the major
connective component for the myocardial scaffold, while type III collagen is more
prominent in vascular adventitia (Frangogiannis, G., 2012). Types IV and V collagen have
also been reported in the heart (Deidre, M., et al., 2000). It is the more pliable type V
collagen that extends and interconnects to the basement membrane components (Deidre,
M., et al., 2000). Together with type IV collagen, the pliable type V collagen will absorb
and transduce the mechanical changes due to alterations in cardiac physiology to the dense,
stiffer types I and III collagen (Deidre, M., et al., 2000).
Cardiac hypertrophy is the process of cardiac wall thickening, and it can be
observed in both the left and right ventricles. Ventricular hypertrophy is caused by a
number of cardiac pathologies, such as hypertension, myocardial infarction, or heart failure
(Ramos, K., & Weber, T., 2010). These pathologies manifest as both chemical and
mechanical changes that impact the overall heart performance; however, it is the
mechanical stressors that are detected by the extracellular matrix proteins, such as type V
collagen and transduced to the cardiac fibroblasts that are responsible for cardiac
extracellular matrix remodeling (Ramos, K., & Weber, T., 2010). Under hypertensive
conditions, cardiac fibroblasts will increase collagen synthesis and decrease collagen
7

degradation (Ramos, K., & Weber, T., 2010). These changes will eventually result in
intercellular fibrosis, ventricular stiffening, and hypertrophy (Bowers, SL., et al., 2010).
With prolonged exposure to hyperglycemia as observed in type II diabetes patients,
advance glycosylated endproducts (AGEs) are being considered as chemical stimuli for
cardiac remodeling (Zhao, J., et al., 2014).
Fibroblasts
Fibroblasts are flat, spindle-shaped cells that are responsible for ECM synthesis and
maintenance. Other types of cells that also participate in ECM synthesis include smooth
muscle cells, which are responsible for elastin secretion, and osteoblasts, which are
specialized fibroblasts responsible for bone synthesis (Peacock, J., et al., 2008). Although
all cells have the ability to synthesize extracellular matrix proteins, there is specificity in
the ECM produced by certain cell types. For example, fibroblasts synthesize connective
tissue ECM, osteoblasts will produce bone, which is calcified ECM, chondroblasts will
secrete cartilage, and epithelia cells are responsible for basement membrane ECM
production (Peacock, J., et al., 2008).
The main function of fibroblasts is to synthesize and maintain the integrity,
structure, as well as function of the ECM. Fibroblasts are also responsible for secreting
multiple different cytokines, growth factors, and pro-fibrotic chemokines, which alter the
synthesis of matrix proteins to further influence the whole heart and tissue function
(Burgess, M., et al., 2002). In addition to ECM proteins, fibroblasts also produce matrix
metalloproteinases (MMPs), which are responsible for ECM protein degradation, and
tissue inhibitors of matrix metalloproteases (TIMPs), which are the responsible for
regulating MMP-mediated ECM degradation (Stewart, JA., et al., 2003). The balancing of
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MMPs degradation and TIMPs production is critical for ECM maintenance. MMPs are
Zn2+-dependent proteases, and they are the dominant proteases for ECM protein
degradation (Stewart, JA., et al., 2003). Different MMP subtypes are responsible for
collagen degradation. For example, MMP1 degrades type I and III collagen in the heart
while MMP2 and MMP9 are responsible for type IV and V collagen degradation (Stewart,
JA., et al., 2003). By producing a balanced level of MMPs and their inhibitors, fibroblasts
can affect ECM homeostasis and remodeling (Stewart, JA., et al., 2003).
Fibroblasts are differentiated from mesenchymal cells. More precisely, they can be
formed from epithelial cells via the epithelial-mesenchymal transition (EMT) under certain
conditions like wound healing (Deidre, M., et al., 2000). Fibrocytes are considered to be
inactive mesenchymal cells, while fibroblasts are thought to be the metabolically active
cell states. Fibroblasts have also been suggested to be derived from fibrocytes of smooth
muscle cells that have become active in response injured tissues (Weber, K., et al., 1989).
Myofibroblasts have been described as being the intermediate cell type between fibrocytes
to fibroblasts transition, which are able to produce the smooth muscle biomarker, alphaactin. EMT has been demonstrated to be a key feature of embryogenesis; however, during
the progression of several pathologies as well as wound healing response, the EMT process
is thought to reoccur (Deidre, M., et al., 2000). Briefly, epithelial cells will lose their
polarity and adhesive cell properties as well as develop a migratory phenotype to become
a mesenchymal stem cell (Deidre, M., et al., 2000). The mesenchymal stem cell can then
differentiate into cells of other various types such as fibroblasts, which would represent the
final “product” of epithelial-mesenchymal transition (Deidre, M., et al., 2000).
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In response to either mechanical or chemical stimuli, such as hypertension or
presence of growth factors, the spindle-like fibroblasts can undergo a reversed EMT
process (Deidre, M., et al., 2000). In particular, this reversed EMT process leads to the dedifferentiation of fibroblasts to myofibroblasts, which are more contractile and smooth
muscle cell-like representing cells derived from a smooth muscle lineage (Weber, K., et al.,
1989). The reversal process of inactive fibrocytes to fibroblasts contributes to an increase
in collagen production; however, the de-differentiation process from fibroblast to
myofibroblast cannot be overlooked (Deidre, M., et al., 2000). Specifically, there are two
steps in the fibroblasts-myofibroblasts de-differentiation.

The fibroblasts will first

differentiate into proto-myofibroblasts, which develop stress actin fibers capable of
generating a contractile force (Deidre, M., et al., 2000). When additional mechanical or
chemical stress is applied, such as increased levels of transforming growth factor-1 (TGF1), the proto-myofibroblasts will develop into myofibroblasts (Deidre, M., et al., 2000). As
mentioned earlier, these myofibroblasts are distinguishable from the proto-myofibroblasts
by the expression of alpha-smooth muscle actin (SMA), which serves as a biological
marker allowing for the generation of greater contractile forces than proto-myofibroblasts
(Deidre, M., et al., 2000). In addition, with the presence of mechanical force or chemical
stimuli, the inactive fibrocytes will be activated and begin the fibroblast differentiation
process (Weber, K., et al., 1989).
With the presence of ECM receptors, such as integrins, on their surface, fibroblasts
can connect to the ECM and detect changes in the extracellular mechanical stimuli. As the
extracellular stressors change, fibroblasts connected to the ECM via integrins will dimerize
and trigger downstream activation of signal cascades to alter collagen expression or
10

degradation to maintain ECM homeostasis (Bowers, SL., et al., 2009). Thus, fibroblasts
actually function as the mechanosensor in this regulation mechanism. Furthermore, other
chemical growth factors, like TGF-beta, can bind to specific growth factor receptors on the
fibroblast plasma membranes and stimulate similar signaling cascades, which also play key
roles in ECM regulation (Bowers, SL., et al., 2009).
A myocardial infarction represents a prime example whereby both mechanical and
chemical stressors act as inducers for both cardiac remodeling and fibroblast activation in
the cardiac remodeling process (Papakrivopoulou, J., et al., 2004). A myocardial infarction
is an acute heart disease, also known as heart attack, caused by the suspension of blood
flow and oxygen to a part of the heart tissue, resulting in cardiac muscle ischemic injury.
Following the myocardial infarction, myocardial repair is triggered by cytokines, such
TGF-beta, which are released from injured myocytes, and serve as chemical cues for
fibroblasts proliferation as well as de-differentiation (Papakrivopoulou, J., et al., 2004).
Fibroblasts will de-differentiate into myofibroblasts and begin to migrate to the edge area
of wound (Papakrivopoulou, J., et al., 2004). Here, the myofibroblasts will begin
contracting to reduce the wound area and form a mature cross-linked scar composed of
ECM proteins (Papakrivopoulou, J., et al., 2004). Types I and III collagen synthesis will
increase and degradation will decrease allowing for both fibroblast and myofibroblastdriven cardiac remodeling process (Papakrivopoulou, J., et al., 2004). In addition, the
inactive mesenchymal stem cells, fibrocytes, can be stimulated by similar growth factors
to begin the EMT process to become myofibroblasts to secrete collagen, and therefore,
contribute to cardiac remodeling (Souders, C., et al., 2009).
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In type II diabetes mellitus patients, a similar process has been observed. Increased
collagen synthesis will alter the plastic of the heart resulting in a stiff, ineffective with poor
heart function (Hutchinson, K., et al., 2013). While excess collagen production could be
the major reason for myocardial stiffening, the persistent exposure to hyperglycemia
condition, which increases collagen glycation, eventually leads to myocardial stiffness and
cardiac contractile dysfunction (Hutchinson, K., et al., 2013).
Advanced glycation end-products (AGEs)
Advanced glycation end-products, or AGEs, are the final products produced
through a non-enzymatic pathway. Normally, AGEs are formed over time as with aging;
however, under certain pathological conditions, the rate of AGE accumulation will increase
(Vlassara, H., and Palace, M., 2002). The formation of AGEs is through a non-enzymatic
glycation process known as Maillard reaction. (Figure 1.2)
Glucose is the major source for glycation products, like AGEs. The open-chain
carbonyl group on carbon atom 1 prime of glucose will interact with an amino group of a
protein, like lysine or arginine residues (Vlassara, H., 2002). Due to the fact that both lysine
and arginine are the most common residues found in protein functional domains, the sugar
carbonyl group will interact with a protein on its lysine/arginine residue to form a reversible
Schiff base product (Hegab, Z., 2012; Vlassara, H., 2012). Following Schiff base formation,
another reversible sugar-protein complex known as the Amadori product, is formed during
the glycation process (Vlassara, H., 2002). Glycation is the process whereby a protein or a
lipid molecule interacts with a sugar molecule to generate a protein-sugar or lipid-sugar
product through an enzyme independent mechanism (Vlassara, H., 2002). This process in
contrast to glycosylation is when an enzyme regulated sugar is added to a protein or lipid
12

product. The post-translational glycosylation modification is one of the key steps for
collagen protein maturation (Hideto, Y., et al., 2004). The lysine residue of collagen is
catalyzed to hydroxylysine by lysyl hydroxylase, and the glycosylation process then occurs
on the catalyzed hydroxylysine (Hideto, Y., et al., 2004). This active lysine residue also
makes collagen a target for the glycation process (Joshi, D., et al., 2009). Once the Amadori
product has formed, it will spontaneously form more stable end products, such as AGE
cross-linked proteins (Hegab, Z., 2012; Vlassara, H., 2012).
Three different methods can be utilized to regulate, control, and prevent the AGE
formation process. The first method is to use desferoxamine, like acetylsalicylic acid. This
has been suggested to be an inhibitor for AGE formation (Voziyan, P., 2002). The second
method is to degrade AGE precursors enzymatically. The glyoxalase system has been used
to degrade reactive carbonyl compounds, such as glyoxal and methylglyoxal, which are
known substrates of the glyoxalase system and are responsible for protein, phospholipid,
and nucleotide glycation (Joshi, D., et al., 2009). The glyoxalase system includes a set of
enzymes responsible for the detoxification of methylglyoxal and other aldehydes.
Glyoxalase I catalyses methylglyoxal isomerization and glyoxalase II hydrolyses the
thiolester to accomplish their detoxification functions (Yadav, S., et al., 2008).
Methylglyoxal, a molecule that has a high potential to be glycated, has been shown to
function as a precursor of AGE formation. Degradation by the glyoxalase system
significantly decreased the methylglyoxal glycation (Joshi D, 2009). Therefore, the
glyoxalase system can inhibit reactive sugar compound accumulation and prevent further
glycation. For the third method, research suggests that the proteasome and lysosome
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systems can sequester and degrade intracellular AGEs and further prevent the AGE-protein
or AGE-lipid cross-linking process (Voziyan, P., 2002).
The cellular, structural, and functional effects of accelerated AGE formation in the
development of diabetic complications are caused by forming cross-links with the main
proteins of the ECM and interacting with its receptor, RAGE. Under hyperglycemia
conditions, AGE can form cross-links with collagen. Studies have suggested that
glucosepane, the lysine-arginine pairs, are the key residues in the collagen functional
domain (Ramasamy, R., 2005). The interaction of AGE and protein can form glucosepanes
due to their relative position and structure and further influence the function of collagen
(Ramasamy, R., 2005). Furthermore, the AGE-collagen cross-links will increase the ECM
area and trap other local macromolecules (Ramasamy, R., 2005). Besides altering the ECM
protein and collagen properties, the AGE-collagen cross-links eventually leads to the ECM
stiffness (Ramasamy, R., 2005).
Note that the AGEs not only generate cross links with collagen, but by interacting
with the AGE receptor, RAGE, multiple intracellular signaling cascades are upregulated
stimulating the expression of TGF-beta, which induces oncogenic transformation and
increases other ECM protein synthesis, such as type I, III, IV, V and VI collagen
(Ramasamy, R., 2005). Therefore, under hyperglycemic conditions the accelerated AGE
formation
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Figure 1.2. Formation of advanced glycation end-products (AGEs). AGEs undergo a nonenzymatic process called the Maillard reaction that involves glucose and proteins, leading
to the formation of a Schiff base. This process occurs over a few hours and is reversible.
Schiff bases are highly unstable and are converted to a more stable compound, called
Amadori product. Amadori products undergo several reactions, over a timespan of months
to years, to produce permanent structural changes via oxidation, dehydration, and
degradation to produce the final, highly stable AGE compound (Hegab, Z., et al., 2012;
Schmidt A., et al., 1999).
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induces multiple collagen cross-link related physiological changes due to the increased
collagen expression. It also alters collagen properties, which results in atherosclerosis
development and cardiac remodeling (Joshi, D., et al., 2009). Overall, AGE increases the
heart tissue stiffness via two aspects: (1) the glycation modification of collagen, where
AGE stiffens the physical properties of the ECM; and (2) the ligand of fibroblasts receptors,
where the AGE increases the speed of collagen synthesis, and contributes to overall
collagen accumulation, eventually leading to tissue stiffness.
Receptor for AGE (RAGE)
RAGE was first identified as the receptor for advanced glycated end-products
(AGEs), and it is a member of immunoglobulin receptor superfamily. The immunoglobulin
superfamily is comprised of cell surface receptors involved in ligand recognition and
binding, and cell-to-cell adhesion (Ramasamy, R., 2005). Members all share similar
structural organization. RAGE is minimally expressed in normal tissue, but has been shown
to be up-regulated under AGE-added conditions (Zhao, J., et al., 2014).
RAGE contains three regions: an extracellular region (contains functional domain
V-type domain, C1-type domain and C2-type domain), a transmembrane region, and an
intracellular region (Lee, E., and Park, J., 2013). The V- and C1-type domains of the
extracellular region form an integrated unit while the C2-type domain is fully independent
(Lee, E., and Park, J., 2013). Different ligands interact with domains including either the
V-type domain, the V-C1-types domain, or the V-C2-types domain (Lee, E., and Park, J.,
2013). Upon ligand binding, RAGE transfers conformational changes into the intracellular
domain (Lee, E., and Park, J., 2013). The cytoplasmic domain of RAGE then interacts with
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formin family member Dia-1, and mediates intracellular signal transmission (Lee, E., and
Park, J., 2013).
RAGE is a pattern recognition receptor because of its ability to recognize multiple
different ligands via a common shared motif. There are four different types of ligands
identified for RAGE: 1) high mobility group protein B1 (HMGB1), 2) S100 calgranulin
family, 3) advanced glycation end-products (AGEs), and 4) amyloid proteins (Lee, E., and
Park, J., 2013). Based on the type of ligand bound, RAGE activates multiple signaling
pathways, including the Ras-ERK1/2 and Cdc42-Rac pathway pathways (Shaw, S.,
2003;Masakiyo, S., et al., 2011). It has been suggested that S100 calgranulin family
activates Ras-ERK1/2 via RAGE and NF-κB, the nuclear factor kappa-light-chain
enhancer of activated B cells, a common activated destination for RAGE signaling
pathways (Shaw, S., 2003;Masakiyo, S., et al., 2011).
The RAGE-mediated signal cascades are depicted in Figure 1.3. First, RAGE will
activate the cyclin-dependent kinase inhibitor p21, a Ras family member (Shaw, S.,
2003;Masakiyo, S., et al., 2011). This activation is followed by mitogen-activated protein
kinase (MAP kinase) activation pathway (Shaw, S., 2003;Masakiyo, S., et al., 2011). MAP
kinase is a serine, threonine, and tyrosine kinase that can induce NF-kB activation, which
stimulates transcriptional gene expression. Another major RAGE-mediated signaling
pathway involved in cell proliferation is Ras-mediated cell division control protein 42
homolog (cdc42) pathway, which promotes cofilin phosphorylation leading to increased
F-actin polymerization (Yan, S., 2003). Ligand-RAGE binding activates p21 activated
kinase (PAK) via p21 (Yan, S., 2003). Once PAK is activated, the downstream factor, Rac
or cdc42, will be stimulated to activate NF-κB directly or JNK/STAT-dependently
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(Souders, C., et al., 2009). The function of NF-κB is to stimulate target gene expression.
Under non-stimuli conditions, NF-κB binds with IκB, the inhibitory protein preventing
nuclear translocation; however, under extracellular oxidative stress conditions, IκB is
degraded, releasing NF-κB for translocation into the nucleus where it binds to response
elements. The DNA/NF-κB complex recruit other proteins like RNA polymerase that
stimulates mRNA transcription (Shuichi, F., 2004). The major cellular responses caused
by RAGE activation are target gene expression stimulation, RAGE up-regulation by
positive feedback, and cytoskeletal remodeling (Yan, S., 2003). Studies have suggested
that RAGE activation is also related to diabetic vascular diseases development and
inflammatory responses. RAGE mediated signaling pathways are depicted in Figure 1.3.
(Hideto, Y., et al., 2004).
In addition to RAGE-mediated diabetic vascular disease, several researchers
suggest that the increased RAGE expression is the major reason for epithelium
inflammatory process (Hideto, Y., et al., 2004). Both in vivo and in vitro findings have
shown that RAGE is involved in inflammatory cells recruitment by functioning as the
receptor of a leukocyte integrin (Metz, V., et al., 2012). Inflammation is a complex
biological response to harmful stimuli and includes tissue repair, new cell proliferation, as
well as cytokine secretion. RAGE can activate the expression of cellular pro-inflammatory
factors and adhesion molecules to increase the inflammatory cells recruitment via the NFkB activation pathway (Yan, S., 2003). In order to eliminate original harmful stimuli, clear
damaged tissue, and initiate tissue repair, the inflammatory process works as a vascular
tissue protective response to those harmful stimuli (Santoni, G., et al., 2015).
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Figure 1.3. RAGE Signaling Cascade. The signaling cascade activated via RAGE and its
ligands varies based on the type of the ligand (Masakiyo, S., et al., 2011). RAGE can
activate members of the Ras family followed by mitogen-activated protein kinases (MAP
kinase) activation to cause NF-κB activation to stimulate transcriptional gene expression.

19

AGE-RAGE Signaling Cascade
Protein Kinase C (PKC)
The protein kinase C (PKC) family is a group of protein kinases that phosphorylates
other proteins via their serine and/or threonine residues. The subtypes of PKC family can
be categorized based on their secondary messengers, such as calcium ions and
diacylglycerol (DAG) (Masakazu, H., et al., 2001). PKC superfamily members share a
common structure, which includes both a regulatory domain and a catalytic domain. The
catalytic domain is highly conserved between different PKC isoforms while the regulatory
domain varies in its secondary messenger requirements (Masakazu, H., et al., 2001). There
are 15 isozymes of PKC family in humans, and they can be divided into three different
subfamilies based on their secondary messenger requirements. The conventional PKC
subfamily (cPKC), including α, β, and γ isoforms, can be activated by either calcium ions,
DAG, or phospholipid (Masakazu, H., et al., 2001). The novel PKC subfamily (nPKC),
which contains δ, ε, η, θ, and μ isoforms, does not require calcium ions for activation,
instead, these isoforms can be activated by DAG and phospholipid (Masakazu, H., et al.,
2001). The atypical PKC subfamily (aPKC) contains ζ, ι, and λ isoforms, and these are
protein kinases and can only be stimulated by phospholipid (Zhao, J., et al., 2014; Pedro,
G., et al., 2010). Due to the different requirements for activation, PKCs can be selectively
activated by certain secondary messenger and provides an intracellular control method
(Pedro, G., et al., 2010).
PKC-ζ belongs to the atypical PKC subfamily. The activation mechanism for PKCζ includes two steps: the first step is to release the pseudosubstrate (PS) sequence from the
substrate-binding domain (Takaaki, H., and Kazuhiro, C., 2003). The second step is the
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catalytic domain activation/phosphorylation. In particular, the PI-3,4,5-triphosphate (PIP3)
has been suggested as the substrate to release the PS sequence from its inhibition domain
of PKC-ζ (Takaaki, H., and Kazuhiro, C., 2003). Therefore, it activates a 3’-PI-dependent
protein kinase 1 (PDK1), which is responsible for PKC-ζ catalytic domain exposure
(Takaaki, H., and Kazuhiro, C., 2003). Once Thr-410 is phosphorylated by PDK1, it
exposes PKC-ζ catalytic domain for further activation (Takaaki, H., and Kazuhiro, C.,
2003). PKC-ζ is fully activated after the Thr-560 auto-phosphorylation (Takaaki, H., and
Kazuhiro, C., 2003). The activated PKC-ζ is then responsible for other downstream
signaling cascades activation, such as mitogen-activated protein kinases (MAPK) cascade
(Takaaki, H., and Kazuhiro, C., 2003).
PKC-ζ signaling
Signaling cascade activation means that a series of regulatory signaling molecules
are activated or phosphorylated leading to a co-responding outcome, such as changes in
gene or protein expression. PKC has been demonstrated to activate major signaling system
via MAPK family (Yu, L., et al., 2003). Both in vivo and in vitro studies illustrate that
PKC-MAPK pathways are activated in the glomeruli of diabetic animals, as well as in
mesangial cells exposure to high glucose levels (Masakazu, H., et al., 2001). The
observation supports the fact that PKC-dependent MAPK activation causes the ECM
accumulation and the diabetic nephropathy progression (Masakazu, H., et al., 2001).
Therefore, it provides a potential therapeutic strategy for diabetic nephropathy treatment
by using MAPK inhibitor.
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In PKC-ζ dependent MAPK activation pathway, the activated PKC-ζ will further
stimulate Raf kinases (Masakazu, H., et al., 2001). The serine/threonine-specific protein
kinases are responsible for the mitogen-activated protein kinase kinase (MAPKK)
activation as well as the phosphorylation of Thr183 and Tyr184 residues of MAPK (ERK)
(Masakazu, H., et al., 2001). ERK is known to activate multiple transcriptional factors,
which are involved in various cellular processes. Transcription factors are molecules that
regulate the gene transcription process by binding to specific DNA sequences (Andrea, O.,
and Sankar, G., 2009).
Under hyperglycemia conditions, AGE shows an increased interaction with its
receptor, RAGE, which generates further signaling pathway via molecular factors Ras. The
activation of Ras in turn stimulates transcription factor expression, such as NF-κB (Shaw,
S., 2003; Zhao, J., et al., 2014). As discussed above, PKC-ζ is suspected to be involved in
the MAPK dependent NF-kB activation pathway and will further develop various
pathological conditions. In particular, the Thr-183 and Thr-184 activated ERK is suggested
to converge in IKK to inhibit IκB, which in turn releases/activates NF-κB (Shuichi, F.,
2004). On the other hand, studies suggest that PKC-ζ is also responsible for direct NF-κB
activation via IκK converging and IκB inhibition (Shuichi, F., 2004).
The nuclear factor kappa light chain enhancer of activated B cell (NF-κB) is one of
the major transcription factors in eukaryotic cells (Shuichi, F., 2004). In addition to
transcription factors, the transcription initiation process, requires RNA polymerase,
components of the general transcription factor, and the energy source, GTP. The functions
of transcription factors include (1) facilitating RNA polymerase binding the TATA box;

22

(2) forming the initiation complex formation; (3) stimulating or repressing target gene
expression by interacting with other transcription factors (Shuichi, F., 2004).
The classical NF-κB activation pathway is regulated by IκB degradation. IκB binds
to the nuclear location signal of NF-κB. Once IκB is phosphorylated by activated IκB
kinases (IKK), the phosphorylation triggers IκB polyubiquitination at Lys 21 and Lys 22,
which is followed by proteasome recognition and degradation. This releases free NF-κB
dimers to enter the nucleus for gene activation. An alternative activation pathway includes
p100 subunit phosphorylation and polyubiquitination by IKK at two C-terminal sites,
followed by the inhibitory C-terminus degradation (Shuichi, F., 2004; Andrea, O., and
Sankar, Ghosh., 2009).
AGE/RAGE mediated Signaling Pathway
Under diabetic conditions, the hyperglycemic environment stimulates AGE
synthesis and increases the RAGE expression due to an increased AGE-RAGE activity
(Hutchinson, K., et al., 2013). The overall AGE-RAGE pathological effects include
increased RAGE expression, increased fibroblast differentiation and increased collagen
production (Fukami, K., et al., 2004). Moreover, the AGE-RAGE signaling pathway has
been demonstrated to be involved in multiple diseases, such as cardiovascular disorder,
arthritis, kidney failure, and diabetes (Zhao, J., et al., 2014). The elevated AGE-RAGE
pathway causes further collagen production while decreasing collagen degradation leading
to collagen accumulation and cardiac fibrosis. Cardiac fibrosis results in the changes to the
mechanical and functional properties of tissues, which finally results in cardiac diastolic
dysfunction (Hutchinson, K., et al., 2013).
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The AGE-RAGE signaling pathway can trigger multiple cellular signaling
pathways where Ras-extracellular signal regulated protein kinase (ERK1/2), Jac2/Stat3,
and NF-κB are involved (Zhao, J., et al., 2014). Therefore, it also stimulates transcription
of other genes. The role of PKC in hyperglycemia-mediated ECM component expression
increases have been previously described, and it is believed that the PKC pathway is
stimulated by a wide range of glucose products, such as hexosamine-6-phosphate, DAG
and AGEs, as well as other endogenous biological compounds (Voziyan, P., 2002). The
downstream signaling cascades spreads out from PKC and regulates multiple cellular
processes that are involved in cell activation and dysfunction.
Research has also shown that PKC-ζ stimulates NF-κB activation via tumor
necrosis factor (TNF) -mediated pathway, which contributes to the increased expression of
growth factors and ECM proteins in mesangial cells (Yuzuru, O., 2005). Furthermore,
AGE-RAGE interaction is believed trigger the phosphorylation of cytoplasmic domain of
RAGE at Ser391 by PKC-ζ (Masakiyo, S., et al., 2011). The Ser391 site phosphorylation
induced by ligand is a prerequisite for the efficiency of other adaptor proteins recruitment;
however, the activation of PKC-ζ requires the activity of another small GTPase, like Ras
GTPase (Masakiyo, S., et al., 2011). The PKC-ζ mediated AGE-RAGE signaling causes
synergistically ERK activation, whereby ERK may function as a molecular bridge between
the two differing cascades (Masakiyo, S., et al., 2011). Based on our preliminary data, we
propose that Rap1a is involved in the AGE-RAGE cascade and may activate PKC-ζ in a
manner similar to Ras GTPase in a hyperglycemic environment.
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Rap1a Signaling Cascade
Rap1a is a member of membranes bound Ras GTPases oncogene family, which are
activated or phosphorylated by cAMP-dependent protein kinase at the C-terminal by
guanine nucleotide exchange factors (GEFs), such as exchange protein directly activated
by cAMP or EPAC (Xiao, C., 2008). GTPases are enzymes that will bind and hydrolyze
guanosine triphosphate (GTP). Rap1a-GTPase can be activated from Rap1a-GDP via
GEFs, which will cause the GDP to be dissociated from Rap1a for a new GTP association
(Xiao, C., 2008). This process can be reversed by GTPase-activating proteins (GAPs)
responsible for GTP hydrolysis (Zhao, J., et al., 2014). Therefore, Rap1a would cycle from
active-inactive-active state by the regulation of GAPs and GEFs. GEFs has been proven to
be activated by several secondary messengers, including DAG, Ca2+, and cAMP (Xiao, C.,
2008).
Rap1a has been demonstrated to be involved in several molecular signaling
pathways (Keiper, M., et al., 2004). Once the G protein coupled receptor is activated by
extracellular ligands, the Gs isoform will translocate and activate the membrane-bound
adenylyl cyclase, followed by the cAMP synthesis (Keiper, M., et al., 2004). Once adenylyl
cyclase is activated, it produces cAMP from ATP. cAMP, the secondary messenger of
multiple signaling cascades. cAMP will then activate EPAC, which functions as the GEFs
of Rap1a molecule that is involved in Rap1a-GTPase activation (Xiao, C., 2008). The
activated Rap1a is then responsible for downstream factors activation, such as ERK1/2.
Similarly, ERK1/2 will get phosphorylated on its Thr183 and Thr184 residues via a Rap1adependent pathway, followed by the transcriptional factor NF-κB activation (Shuichi, F.,
2004).
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NF-κB is a transcriptional factor that shares a Rel homology domain at the Nterminal. It contains two immunoglobulin-like subdomains responsible for DNA major
groove binding (Selvi, C., 2011). The C-terminal dimerization domain is the IkB
interaction site. Once the inhibitor IκB is activated by other kinases, like PKC-ζ, NF-κB
will be released/activated and translocated into the nucleus for other transcriptional factor
activations, such as c-jun. c-jun N-terminal kinases (JNKs), which belongs to the MAPK
family. Together with c-fos, c-jun will form the activator protein 1 (AP1) transcriptional
factor. JNKs are activated by phosphorylation of the threonine and tyrosine residues within
the subdomain VIII by MKK4 and MKK7. JNKs are involved in multiple cellular
processes by phosphorylating/activating downstream molecules (Andrea, O., and Sankar,
Ghosh., 2009).
Extracellular signal regulated kinases 1 and 2 (ERK1/2) are also members of MAP
kinases but are specific to N-terminal serine, threonine, and tyrosine phosphorylation.
ERK1/2 are involved in cell proliferation regulation (Masahiko, I., et al., 1998). They can
be activated at the Thr-183 and The-184 residues via a Ras-dependent pathway. Ras
activates c-Raf, followed by the MKK activation. The activated MKK then further
phosphorylates MAPKs.
Little is known about the interaction between Rap1a and AGE-RAGE signaling
cascades in type II diabetes mellitus. Correlative studies have demonstrated that the Rap1a
pathway is PKA-dependent and triggers ERK1/2 activation (Fukami, K., et al., 2004; Joshi,
D., et al., 2009). Further studies have described that both the AGE-RAGE signaling
pathway and Rap1a cascade activate similar downstream factors, such as ERK1/2, NF-κB,
and JNK. Although Rap1a and AGE-RAGE are shown to be associated with the increased
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interstitial fibrosis and myofibroblasts formation, independently, their inter-relationship or
the existence of cause-effect relation between the cascades remains inconclusive.
We propose that the AGE-RAGE signaling cascade is intersected by Rap1a.
Altering this interaction will lead to changes in the activation of downstream players of the
AGE-RAGE signaling cascade, as seen in Figure 1.4. Activation or elimination of Rap1a
will also lead to changes in the three known outcomes of the AGE-RAGE cascade, which
includes fibroblast differentiation, RAGE expression, and collagen production (Zhao, J., et
al., 2014). Specifically, when the AGE-RAGE signaling pathway is activated, the three
significant outcomes will contribute to long-term complications of diabetes, and
suppression of Rap1a activity or protein expression will dampen the effects of the AGERAGE molecular cascade.
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Figure 1.4. Representative AGE-RAGE and cAMP/PKA-Rap1a signaling cascades.
Hyperglycemia, with pre-diabetes or diabetes, increases the crosslinking of structural
protein collagen with the excessive glucose increasing the rate of advanced glycation endproducts (AGEs) formation on extracellular matrix. AGEs bind to their receptor, receptor
for advanced glycation end-products (RAGE), creating downstream signaling events to
activate protein kinase C-ζ (PKC-ζ) and leading to activation of mitogen-activated protein
kinase (MAPK). Once activated, transcription factor extracellular signal-regulated kinase
1/2 (ERK1/2) creates three known outcomes: increase in fibroblasts differentiation into
myofibroblasts, increase in RAGE expression, and increase in collagen production.
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Animal Model
The diabetic mice model used was a 16-week old male Leprdb (db/db) type II
diabetes mellitus mice (BKS.Cg-Dock7m +/+ Leprdb/J, Jackson Labs). This mouse model
has a G->T point mutation in the leptin receptor, which causes nonfunctional leptin
receptors. The G->T mutation results in an insertion of a 106 nucleotide in leptin receptor
mRNA transcript and a premature stop codon expression. The long intracellular domain
translated by the leptin receptor mRNA is crucial for initiating intracellular signal
transduction, and as a corollary, the premature stop codon expression and the inability to
produce this form leads to the Ob-Rb isoform (Chen, H., et al., 1996). Leptin signaling
cascade triggers the communication to the central nervous system (CNS) under the
condition that there is abundant energy existing, and further control food intake. With this
mutation, the leptin receptor loses its sensitivity to leptin as well as its CNS communication
function. Therefore, the mice will continue to eat, eventually resulting in obesity and
insulin resistance, which are two key characteristics of type II diabetes mellitus. The mice
develop hyperglycemia by 8-weeks of age, overt diabetes by 12-weeks of age, and share
many other common features with type II diabetes mellitus including hyperglycemia,
obesity, and insulin resistance.
Background of Cell Treatments
8-CPT-2Me-cAMP
8-CPT-2Me-cAMP, or EPAC Agonist, is used in gain-of-function studies due to its
ability to activate Rap1a directly and specifically. EPAC is cAMP sensitive guanine
nucleotide exchange factor (GEF) and 8-CPT-2Me-cAMP is a selective activator for EPAC
(Jeyaraj, S., et al., 2012).
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Rap1a siRNA
Silencing Rap1a mRNA is used for loss-of-function studies. There are two steps
for siRNA function once it enters fibroblast nucleus via a lipid vesicle. The first step is the
degradation of double stranded RNA into small interfering RNAs via RNase III. The
second step is the package formation of siRNAs and RNA-induced silencing complex
(RISC). The formed complex then binds to and degrades the complementary mRNA for
the target protein, Rap1a.
PKC-ζ Pseudo-substrate
PKC-ζ Pseudo-substrate (PS) is a reversible Ser/Thr protein kinase inhibitor for
PKC-ζ (Santa Cruz, 2016). It is a substrate competitive inhibitor, which means PS is
competing with other substrates for PKC-ζ binding preventing PKC-ζ kinase activity.
However, the binding of PS with PKC-ζ does not cause a conformational change, therefore,
the signaling via PKC-ζ activation is blocked.
UO126
UO126 is a highly selective inhibitor for both MEK1 (IC₅₀ = 72 nM) and MEK2
(IC₅₀ = 58 nM) (Santa Cruz, 2016). The inhibition is noncompetitive with respect to MEK
substrates, such as ERK. Therefore, in this study, UO126 is used as the specific inhibitor
to block ERK1/2 activation.
AGE-BSA
AGE-BSA (advanced glycated end-products-bovine serum albumin) is a RAGE
agonist (Sigma-Aldrich). It activates the RAGE receptor by increasing the number of AGEs
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present. AGE-BSA is produced via Maillard reaction by BSA interacting with
glycolaldehyde. The formed complex is further stabilized as an Amadori product to
generate the final AGE compound.
Universal Control
The universal control was run on every 10% sodium dodecyl sulfate
polyacrylamide gel (SDS-PAGE) together with other sample proteins. The universal
control was composed of an evenly aliquoted amount from four different untreated nondiabetic (Het) fibroblast isolations. Each fibroblast isolation used hearts from 2-3 mice per
isolation. The use of universal control allows for the cross comparison of Western blots.
Specific Aims
Previous studies showed evidence that in type II diabetes mellitus, hyperglycemic
conditions influenced cardiac fibroblasts phenotype changing, induced collagen
accumulation, and increased RAGE receptors expression. The increased AGE/RAGE
signaling cascade was implicated in the potentiation and pathogenesis of cardiovascular
diabetic complications. In preliminary studies, we observed that left ventricle (LV)
collagen levels were significantly decreased in Rap1a knockout mouse hearts, and by
silencing Rap1a mRNA in diabetic fibroblasts, collagen production and RAGE expression
returned to that of non-diabetic levels. Even though both the AGE/RAGE signaling cascade
and Rap1a utilize and activate similar signaling pathways involved in cell growth, ECM
synthesis and fibroblast differentiation, which include downstream factors, ERK1/2 MAP
kinases, PKC-ζ, NF-κB and JNK, the molecular mechanism governing type II diabetes
mellitus mediated alterations in cardiac fibroblasts are not well understood. The purpose
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of this work is to find and describe the novel molecular mechanism of Rap1a dependent
AGE/RAGE signaling involved in diabetic cardiac fibroblasts remodeling and myocardial
ECM protein accumulation. Therefore, the hypothesis proposed is that diabetes induces
increased AGE/RAGE signaling which is mediated by active Rap1a GTPase resulting in
elevated signaling outcomes, such as RAGE, fibroblast differentiation, and collagen
expression, in heart. The following specific aims were used to test the hypothesis.
Specific Aim 1
Define a functional link between Rap1a and AGE/RAGE signaling cascades. We
propose that the Rap1a and AGE/RAGE signaling cascades will converge at PKC-ζ to
stimulate the downstream mediator ERK. Deactivation of this mechanism by utilizing a
loss-of-function approach could lead to reduced fibroblast phenotype changes, decreased
collagen accumulation and RAGE down-regulation. The genetically diabetic (db/db)
mouse and lean (Db/db) control will be used to determine the mechanistic relationship of
the Rap1a and AGE/RAGE cascades. Loss-of-function studies should restore diabetic
signaling back to non-diabetic levels.
Specific Aim 2
Determine whether changes in Rap1a GTPase expression will affect diabetesmediated AGE/RAGE signaling in vitro. We propose that by using a gain-of-function
approach, Rap1a activation will stimulate increases in the AGE/RAGE signaling cascades.
These cascades will converge at PKC-ζ to stimulate the downstream mediator ERK.
Activation of this mechanism could lead to the subsequent fibroblast phenotype changes,
increased collagen accumulation and RAGE up-regulation. The lean (Db/db) control will
32

be used to determine the mechanistic relationship of the Rap1a and AGE/RAGE cascades.
Gain-of-function studies should exacerbate non-diabetic signaling to that of diabetic levels.
Specific Aim 3
Determine whether changes in Rap1a GTPase expression affect diabetes-mediated
AGE-RAGE signaling in vivo. Rap1a gene ablation in diabetic mice was proposed to
determine changes in ECM accumulation, RAGE expression, and fibroblast differentiation.
However, db/db Rap1a-/-mice died at 4-5 weeks of age, much earlier than the required endpoint of 15-16 weeks old. An alternative method of high fat diet feeding was used to
develop type II diabetes in Rap1a+/- mice. We will measure the physiological parameters
of the mice (i.e., heart weight, body weight, and fasting blood glucose measurement) and
then determine the intersecting molecular signaling mechanisms by which Rap1a mediates
in vivo changes in the AGE-RAGE cascade.
Significance
The successful completion of this project defines the molecular mechanisms
involved in Rap1a-mediated AGE/RAGE signaling in type II diabetic hearts. These studies
are the first of its kind to provide unique targets for therapeutic strategies aimed at reducing
hyperglycemia-mediated ECM production and accumulation in diabetic patients.
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Figure 1.5. Schematic representation of specific aims. Three specific aims were proposed
to test our hypothesis. The first aim used a loss-of-function treatment to down-regulate
Rap1a expression in vitro. The second aim used a gain-of-function treatment to up-regulate
Rap1a expression in vitro. The third aim used genetically Rap1a defection mice model to
test on molecules involved in AGE-RAGE signaling pathway in vivo.
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CHAPTER III
MATERIALS AND METHODS
Animal Model
The genetically diabetic mice model is Leprdb (db/db) type II diabetes mellitus mice
(BKS.Cg-Dock7m +/+ Leprdb/J, Jackson Labs), which has a leptin receptor mutation. The
heterozygous lean littermates (Het) were used as controls. The Rap1a knockout model has
a reversed neomycin cassette inserted into exons 2 and 3 (Yu, L., et al., 2007). All mice
were housed under standard environmental conditions and maintained on commercial
mouse chow as well as tap water ad libitum. All studies used male mice and followed the
principles of the National Institutes of Health “Guide for the Care and Use of Laboratory
Animals,” (NIH publication No. 85-12, revised 1996) and the protocol was approved by
the Mississippi State University Animal Care and Use Committees (IACUC protocol
number 14-046). Once the animal model reached 15-16 week of age, they were euthanized
using carbon dioxide inhalation, followed by heart isolation for further cellular and
biochemical experiments. Physiological measurements, such as body weights, non-fasting
blood glucose, and heart weights, were taken prior to cell isolations.
Cell Isolation
Cardiac fibroblasts were isolated from heart tissue using a modified protocol by
Burgess et al. (Burgess, M., et al., 2002). Ventricles were dissected from extra-cardiac
tissue and atria, minced into 2mm pieces, rinsed by ice cold sterilized phosphate buffered
35

saline and digested with type II collagenase (240 U/mg; Worthington Biochemical) for 10
minutes, supplemented with 0.25% Trypsin (Life Technologies) in a water jacketed spinner
flask. The supernatant was collected in a sterilized 50 mL tube, and Dulbecco Modified
Eagles Medium (DMEM) containing 20% Fetal Bovine Serum (FBS) was used as the stop
buffer to quench enzyme function. A 10-minute centrifugation step 170g was performed to
collect isolated cells pellet. The collected cells were then resuspended and maintained in
DMEM media with 15% FBS, 1X L-glutamine (Fisher Science), and 2X Primocin®
antibiotic and antimycotic (Fisher Science) under 37°C temperature. Cells were plated on
60 mm dishes, and fibroblasts were isolated/purified through attachment to tissue culture
plastic. Fibroblasts from diabetic animal model were maintained in high glucose DMEM
(4.5 g glucose/L) while non-diabetic fibroblasts from heterozygous and control animal
groups were maintained in normal glucose DMEM (1 g glucose/L). All experiments were
performed using cells at P0-P1 in order to maintain their original phenotypes. A visual
confirmation was performed for cell type determination. Cells were passaged just prior to
reaching 95% confluency using a 0.25% trypsin, 0.1% ethylenediaminetetraacetic acid
(trypsin/EDTA) solution (Life Technology). Hearts from 2-3 mice were used per isolation.
Data from 2-3 independent isolations were collected per group.
Cell Treatments
To obtain quiescent cells, fibroblasts at 90-95% confluency were serum starved for
24 hours in 0.01% FBS DMEM. The media was changed back to culture media 1 hour
after serum starvation. Cells were then treated with the following drug doses together or
separately for 24 hours as indicated. Drug doses: 8-CPT-2Me-cAMP (EPAC Ag; Sigma
Aldrich; 100μM dissolved in sterile PBS); Rap1a siRNA (Santa Cruz Biotechnology; 10
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μM dissolved in sterile RNase free water); PKC-ζ pseudo-substrate (PS; Sigma Aldrich; 1
μg/mL, dissolved in sterile PBS); UO126 (Sigma Aldrich; 5 μM, dissolved in sterile
DMSO). Treatment of glycated albumin AGE-BSA (Sigma Aldrich; 0.5 mg/mL, dissolved
in sterile PBS) was performed on all experimental groups for an additional 24 hours, except
for the control group.
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Figure 2.1. Timeline of isolated cardiac fibroblast treatments. Isolated cells were grown to
95% confluency followed by serum starvation for 24 hours with 0.01% Fetal Bovine Serum
(FBS) in Dulbecco Modified Eagles Medium (DMEM) on Day -1. On Day 0, cells were
treated with either EPAC agonist (8-CPT-2Me-cAMP or 8-CPT) for a gain-of-function
study or Rap1a siRNA for a loss-of-function study. In addition, pharmacological inhibitors
of phospho-PKC-ζ (PKC-ζ Pseudosubstrate, or PS) or phospho-ERK1/2 (UO126) was
added to the culture plates at same time as Rap1a siRNA or 8-CPT was administered.
Following 24 hours (Day 1), cells were treated with AGE-BSA to robustly activate RAGE.
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Picric Acid Sirius Red (PASR) Stain
Hearts were fixed in 10% buffered formalin and embedded in paraffin blocks.
Blocks were sectioned at 5-µm thickness from the equator of the heart and stained with
Picric Acid Sirius Red F3BA (HSRL, Inc.). Estimates of the fractions of thick and thin
collagen fibrils were obtained by using polarized light. Due to the birefringent quality of
the stain, collagen refracted a distinct color based upon the size of the collagen fibrils: red
and yellow (thick filaments) and green (thin filaments). Quantitative analysis was
accomplished by light microscopy with a video-based image-analyzer system. Color
thresholds were set for biphasic analysis to capture and generate a percent collagen
content per 40x field within the specified RGB wavelength ranges separate from the
background: Phase 1 represents collagen capture Red (0-40) Green (0-80) Blue (0-255)
and Phase 2 represents background capture: Red (20-255) Green (40-255) Blue (35-255).
Soluble-Insoluble Collagen Content Measurement
100 mg of cardiac tissue was mixed with 3 ml of 200 µg/ml pepsin in 0.5 M
acetic acid and incubated at 37°C with gentle agitation. Following 2 hours of digestion,
samples were centrifuged at 20,000g for 20 minutes at 4°C and 1 mL of supernatant was
removed to be frozen at -80°C. The pellet was re-suspended in the remaining supernatant
to be incubated at 37°C with gentle agitation for 24 hours. Following 24 hours of
digestion, samples were centrifuged at 20,000g for 20 minutes at 4°C and another 1 mL
aliquot of supernatant was removed to be frozen at -80°C. The pellet was then resuspended in the remaining supernatant to be incubated at 110°C in a 6 M HCl solution
for 18 hours. Following 18 hours of 6 M HCl digestion, samples were centrifuged at
20,000g for 20 minutes at 4°C and 1 mL of supernatant was discarded. The remaining
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pellet was re-suspended in deionized water and frozen at -80°C. Sircol™ collagen assay
(Biocolor, Ltd., Ireland) was performed according to manufacturer’s instructions. The
conditions for pepsin digestion were chosen, so that significant solubilization of the
unmodified or soluble collagen was identified at 2 hours and 24 hours, which maximum
solubilization (>98%) was observed (Candido, R., et al., 2003). Insoluble collagen
content was determined by measuring collagen concentration after 18 hours acid
hydrolysis using the procedure of Stegemann and Stalder (Stegemann, H., and Stalder,
K., 1967). Collagen content was expressed as μg of collagen per mg of wet weight of
heart tissue.
Protein Isolation
After cell treatment, fibroblasts were harvested and proteins isolated as follows.
The media was collected, and stored at -80°C as ‘conditioned media’ for future biochemical
assays. Cultured cells were washed with 1X PBS to remove any remaining conditional
media, and the 1X PBS removed by vacuum aspiratation. 200 μL volume of modified
Hunter’s Buffer (1% Triton X-100, 75 mM NaCl, 5 mM Tris pH 7.4, 0.5 mM
orthovanadate, 0.5 mM EDTA, 0.5 mM EGTA, 0.25% NP-40, and protease inhibitors) was
added and the cells incubated at room temperature for 10 minutes. Cells were removed by
scraping off and transferred to a 1.5 mL centrifuge tube. Following a 5 second sonication,
the cells were centrifuged for 15 minutes at 20,000g at 4°C and the supernatant collected
and transferred to a new 1.5 mL centrifuge tube for further analysis.
The protein sample concentration was determined using bicinchoninic acid (BCA)
assay (Pierce Biotechnology). A standard protein concentration curve was generated by
using a serial dilultion of bovine serum albumin (BSA) from 2.0 mg/mL to 0.0 mg/mL.
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The sample protein level was calculated using GraphPad (Prism 5 Software) based on the
optical density (OD) value reading at 462 nm.
Immunoblot Analysis
Equal amount of protein sample (25-50 µg) loaded and separated by SDS-PAGE
(stacking gel with 5% SDS-PAGE, pH6.8, separating gel with 10% SDS-PAGE, pH8.8)
were transferred to PVDF membrane in Tris-Glycine-Methanol buffer at 100mA at 4°C for
approximately 18 hours. Coomassie brilliant blue was used for membrane staining to
identify potential transfer problems. Membranes were incubated in 5% non-fat milk or 5%
FBS depending upon antibody requirements in TBS-Tween (0.1%) to block non-specific
protein binding, followed by specific primary antibody incubation, which was able to
recognize and bind to denatured target protein antigen. The target proteins conclude the
cardiac fibroblast bio-maker: α-smooth muscle actin (α-SMA; Sigma-Aldrich); the ECM
regulators: RAGE (Abcam); the signaling proteins: PKC-ζ, ERK1/2 and Rap1a (Santa
Cruz Biotechnologies); and GAPDH (Santa Cruz Biotechnologies) was used as the loading
control. The secondary antibody was linked to horseradish peroxidase (HRP) and the
membrane developed using luminol (Thermo-Fisher). Primary and secondary antibodies
were used at 1:1000 dilution.
Developed films were scanned and NIH Image J was used to measure blot density
and generate arbitrary densitometric units based on intensity of bands. The densitometric
measurements of the protein of interest were normalized to its loading control (GAPDH).
Immunoblots were stripped and reprobed. Loading controls were run for every blot. The
normalized protein values were then divided by normalized universal control protein values,
41

and thus setting the universal control to 100%. Experimental groups were represented as a
fold above or below the universal control.
High Fat Diet Treatment
The Rap1a wildtype and heterozygous mice were placed on a high fat diet
(Research Diet D12492 Rodent Diet with 60% kcal from fat). This diet has been reported
to cause the onset of clinical diabetic conditions, such as hyperglycemia and obesity
(Skovsø, S., 2014). Mice were started on the high fat feed at 4 weeks of age and were kept
on the diet for 12 weeks, at which time the mice were 16 weeks old. The diet was replaced
twice a week as it was found to turn rancid 2-3 days after exposure to room temperature.
Weekly tail snips to measure blood glucose and body weight measurements were
recorded to monitor the onset of hyperglycemia and obesity. At 16 weeks of age, mice were
fasted overnight and physiological measurements, which included fasting blood glucose
levels, body and heart weights, were taken prior to sacrifice and cell isolation.
Glucose Measurements
Blood glucose measurements were taken using a glucose meter (or glucometer),
which is a medical device used to approximate the concentration of glucose in the blood.
Briefly, the tip of the mouse’s tail (~3-5 mm) was snipped off and a drop of blood was
placed on a disposable test strip.
Genotyping
Genotyping was performed to identify homozygotes for our studies. Tail snips (~35 mm) were obtained and placed in 250 µl of DNA extraction buffer (50mM sodium
hydroxide). Tails were minced into small pieces and incubated at 95°C for 60 minutes. The
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reaction was neutralized with 20 µl of 1M Tris-HCl (pH 8.0). Samples were centrifugation
at 20,000g for 5 minutes to remove undigested materials. DNA samples were stored at
-20°C. Forward and reverse primers, as well as the thermocycler protocol for the
genotyping of the mice, are given below.
Primers for genotyping leptin receptor (Db):
Db Forward 1 (F):

5´‐ AGAACGGACACTCTTTGAAGTCTC -3´

Db Reverse 1 (R1):

5´‐ CATTCAAACCATAGTTTAGGTTTGTGT -3´

Db Reverse 2 (R2):

5´‐ GGCCACAAAATATACACTTCTCTAATAAGCTC -3´

Procedure for first step of genotyping leptin receptor (Db):
The first PCR step is carried out as described below in tables 1 and 2. Briefly, the
PCR samples comprised 1μL of genomic DNA, 15 μL of Taq 2×PCR master mix, 1 μL of
100 μM (dissolved in nuclease free water) of forward Db-F primer, 1 μL of 100 μM
(dissolved in nuclease free water) of reverse Db-R2 primer, and 12 μL of RNA free water
for a total volume of 30 μL. Target DNA was amplified with initial denaturation at 94°C
for 5 minutes, followed by 30 cycles of denaturation at 94 °C for 30 seconds, annealing at
53 °C for 30 seconds, extension at 72°C for 30 seconds and elongation step at 72°C for 5
minutes.
PCR Master Mix
2X Taq Mix
Forward Primer Db-F
Reverse Primer Db-R2
RNA Water

15.0 μL
1.0 μL
1.0 μL
12.0 μL

Table 1. Master Mix content table for for first step of leptin receptor genotyping
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Temperature
94˚C
94˚C
53˚C
72˚C
72˚C
4˚C

Time
5 min
30 sec
30 sec
30 sec
5 min
Hold

Cycles
X1
X 30
X1

Table 2. Genomic PCR amplification conditions for first step of leptin receptor genotyping
After the first step of the leptin receptor (Db) genotyping, the DNA products were
run through a clean-up kit (Qiagen; Fermentas GeneJet PCR Purification Kit #K0702).
According to the manufacturer’s protocol, 30 μL of PCR products were mixed with equal
volumes of isopropanol (50 μL) and binding buffer (50 μL) and after which the mixture
was centrifuged for 60 seconds at 20,000g and effluent discarded. The bound DNA was
then washed with wash buffer containing ethanol, centrifuged for 60 seconds at 20,000g,
and the effluent discarded. This was followed by a dry spin in which samples were
centrifuged for 60 seconds at 20,000g. Lastly, the filter column was transferred to a new
microcentrifuge tube, 50 μL of elution buffer was added, centrifuged for 60 seconds at
20,000g, and purified DNA was stored at -20°C until used for the second step of the leptin
receptor (Db) genotyping, which is outlined below, as well as a digestion step required to
determine mouse genotype.
Procedure for second step of genotyping leptin receptor (Db):
The second PCR step was carried out as described below in table 3 and 4. Briefly,
the PCR samples comprised 0.5 μL of first step PCR reaction, 15 μL of Taq 2×PCR master
mix, 1 μL of forward Db-F primer of 100 μM (dissolved in nuclease free water), 1 μL of
reverse Db-R1 primer of 100 μM (dissolved in nuclease free water) , and 12.5 μL of RNA
44

free water to add total volume up to 30 μL. Target DNA was amplified in a thermocycler
machine, with initial denaturation at 94°C for 5 minutes, followed by 30 cycles of
denaturation at 94 °C for 30 seconds, annealing at 53 °C for 30 seconds, extension at 72°C
for 30 seconds and elongation step at 72°C for 5 minutes.
PCR Master Mix
2X Taq Mix
Forward Primer Db-F
Reverse Primer Db-R1
RNA Water

15.0 μL
1.0 μL
1.0 μL
12.5 μL

Table 3. Master Mix content table for second step of leptin receptor genotyping
Temperature
94˚C
94˚C
53˚C
72˚C
72˚C
4˚C

Time
5 min
30 sec
30 sec
30 sec
5 min
Hold

Cycles
X1
X 30
X1

Table 4. Genomic PCR amplification conditions for second step of leptin receptor
genotyping
Digestion Step:
The digestion step was carried as described below in Table 5. Briefly, the PCR
samples comprised 8.5 μL of second step PCR reaction, 1.5 μL of 10× Tango Yellow buffer
(Thermo Fisher), 1.5 μL of RsaI (10 U/L, Thermo Fisher), and 3.5 μL of RNA free water
to add total volume up to 15 μL. Target PCR reaction sample was incubated at 37˚C for 2
hours. RsaI restriction enzyme recognizes GT^AC sites and was used to cut generated PCR
products from the two-step nested leptin receptor (Db) genotyping.
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Digestion Mix
10X Tango Yellow buffer
Rsa1
RNA Water

1.5 μL
1.5 μL
3.5 μL

Table 5. Digestion Mix content table for leptin receptor genotyping
Procedure for gel:
A 3% agarose gel is used to separate PCR products. The gel was run for 1 hour at
100 V. 5 μL Ethidium bromide per 100 mL agarose is loaded into the gel to visualize the
DNA PCR products. 15 μL of samples and 3 μL of dye are loaded into gel with 1X TAE
of running buffer. The gel is visualized under UV light and an image was taken to record
for genotyping of mice. The result of gel visualization for leptin receptor genotyping is
shown in Appendix A1.
Primers used for genotyping Rap1a:
ADPR266:

5´‐ TCTATCGCCTTCTTGACGAGTTC -3´

Rap1aKO:

5´‐ CTTGCTCTCCTGTTACCTATAGGTGCC -3´

RapExon:

5´‐ CCGTAAAATCTGTTCTCTCAAGTC -3´

Procedure for genotyping Rap1a:
The PCR step for Rap1a genotyping is carried out as described below in table 5 and
6. Briefly, the PCR samples comprised 2 μL of genomic DNA, 15 μL of Taq 2×PCR master
mix, 1 μL of 100 μM (dissolved in nuclease free water) of ADPR266, 2 μL of 100 μM
(dissolved in nuclease free water) of Rap1aKO primer, 1 μL of 100 μM (dissolved in
nuclease free water) of RapExon primer, and 14 μL of RNA free water to add total volume
up to 35 μL. Target DNA was amplified in a thermocycler machine, with initial
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denaturation at 93 °C for 1.5 minutes, followed by 40 cycles of denaturation at 93 °C for
30 seconds, annealing at 57 °C for 30 seconds, extension at 65 °C for 3 minutes and
elongation step at 65 °C for 3 minutes.
PCR Master Mix
2X Taq Mix
ADPR266
Rap1aKO
RapExon
RNA Water

15.0 μl
1.0 μl
2.0 μl
1.0 μl
14.0 μl

Table 6. Master Mix content table for Rap1a genotyping
Temperature
93˚C
93˚C
57˚C
65˚C
65˚C
4˚C

Time
1.5 min
30 sec
30 sec
3 min
3 min
Hold

Cycles
X1
X 40
X1

Table 7. Genomic PCR amplification conditions for Rap1a genotyping
Procedure for gel:
A 1% agarose gel is used to separate PCR products. The gel was run for 1 hour at
100 V. 5 μL Ethidium bromide per 100 mL agarose is loaded into the gel to visualize the
DNA PCR products. 15 μL of samples and 3 μL of dye are loaded into gel with 1X TAE
of running buffer. The gel is visualized under UV light and an image was taken to record
for genotyping of mice. The result of gel visualization for Rap1a genotyping is shown in
Appendix A2.
Statistical Analysis
The protein expression was quantified using ImageJ software, and the statistical
difference analysis performed via unpaired students’ T-test using GraphPad Prism 5.
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Significance was defined as p<0.05. Error bars represent ± standard error of the mean
(SEM). Differences in physiological parameters were performed via ANOVA using
GraphPad Prism 5. Significance was defined as p<0.05. Error bars represent ± standard
error of the mean (SEM).
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CHAPTER IV
RESULTS
The purpose of this study was to define the molecular link between Rap1a GTPase
and cardiac complications common to type II diabetic patients. Initial studies by our
laboratory demonstrated elevated expression levels of collagen, RAGE, and α-smooth
muscle actin (α-SMA), a marker for fibroblast to myofibroblast differentiation in diabetic
fibroblasts (Hutchinson, K., et al., 2013). These changes in cellular protein expression were
accompanied by decreased diastolic function in the diabetic heart (Hutchinson, 2013). In
addition, AGE-RAGE signaling was shown to be a major driving factor for diabetic heart
remodeling (Hutchinson, K., et al., 2013). Despite the body of knowledge surrounding
AGE-RAGE signaling, there are several molecular players involved in this cascade that are
still unknown. Initial data from our laboratory reported by Zhao et al., introduced a
potential role for Rap1a GTPase as a regulatory mechanism for diabetic complication,
Figure 3.1 (Zhao, J., et al., 2014). Decreasing Rap1a expression using siRNA treatment in
non-diabetic (Het) and diabetic (db/db) isolated cardiac fibroblasts resulted in a knockdown
of Rap1a expression as well as decrease in signaling molecules, such as phospho-PKC-ζ
and phospho-ERK1/2. Additionally, AGE-RAGE cascade outcomes, such as RAGE,
collagen, and α-SMA, were reduced to non-diabetic levels. Therefore, the hypothesis
proposed for this dissertation work was that diabetes induces increased AGE-RAGE
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signaling, which is mediated by active Rap1a GTPase resulting in elevated ECM
accumulation in heart.
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Figure 3.1. Representative western blot depicting protein expression in non-diabetic (Het)
and diabetic (db/db) fibroblasts treated with either scrambled siRNA [(-)siRNA] or Rap1a
siRNA (Zhao, J., et al., 2014). Rap1a siRNA treatment in diabetic (db/db) fibroblasts
resulted in decreased protein expression for phospho-PKC-ζ, phospho-ERK1/2, RAGE,
collagen, and α-SMA to levels similar in non-diabetic (Het) cells. GAPDH protein
expression was used as a loading control to ensure even gel loading.
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Additional data obtained by our laboratory demonstrated a change in collagen
levels based upon Rap1a allele penetrance. Mid-ventricular sections of hearts from Rap1a
wild-type (Rap1a+/+ WT), Rap1a heterozygous (Rap1a+/- Het), and Rap1a knockout
(Rap1a-/- KO) were stained with picric acid-sirius red (PASR) and visualized under
polarized light. Collagen from PASR stained histology sections will “emit” a light due to
the bifuringent properties of the stain (Hutchinson, 2013). As shown in Figure 3.2, there
was a significant decrease in total collagen levels based on the varying degrees of presence
or absence of Rap1a alleles. Further studies were performed to measure the soluble and
insoluble collagen levels present in the hearts of Rap1a wild-type (Rap1a+/+ WT), Rap1a
heterozygous (Rap1a+/- Het), and Rap1a knockout (Rap1a-/- KO). Further studies showed
that both soluble and insoluble collagens were significantly reduced in (Rap1a-/- KO) mice.
Changes in soluble or immature collagen versus changes in insoluble or mature, crosslinked collagen represent alterations in either the synthesis, maturation, or degradation
pathways (Hutchinson, 2013). For these results, Rap1a-/- KO mice had significantly lower
rate of collagen synthesis and maturation in comparison to both the Rap1a wild-type
(Rap1a+/+ WT) and Rap1a heterozygous (Rap1a+/- Het) (Figure 3.3). Zymograms were
then performed to measure matrix metalloproteinase (MMP) activity (data not shown).
There were no measurable differences between groups. Therefore, decreased levels of
soluble and insoluble collagen appear to be the result of reduced collagen production and
maturation. Based on these findings, Rap1a was observed to mediate a notable degree of
regulation within the AGE-RAGE signaling cascade as well as controlling the level of
collagen expression.
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Figure 3.2. Collagen from picric acid-sirius red (PASR) stained hearts. Collagen fibrils
were obtained by using polarized light and were pointed by arrows showed in the graph.
Collagen volumes were decreased in Rap1a -/- KO compared to Rap1a +/+ WT as
represented in the graph. Collagen levels from Rap1a +/+ WT, Rap1a +/- Het, and Rap1a
-/- KO mice appear to model allele penetrance. Rap1a -/- KO mice have approximately a
50% decreased expression compared to Rap1a +/+ WT mice. *p<0.05 vs. Rap1a +/+ WT
mice. Magnification = 400X.
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Figure 3.3. Insoluble and soluble collagen values in ventricular samples from Rap1a +/+
WT, Rap1a +/- Het, and Rap1a -/- KO mice appear to model allele penetrance. Rap1a -/KO mice have significantly decreased levels of insoluble (mature) and soluble (immature)
collagen compared to Rap1a +/+ WT mice. *p<0.05 vs. Rap1a +/+ WT mice
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Cardiac fibroblasts were then isolated from both genetically diabetic (db/db) and
lean (Het) mice. Rap1a protein expression was shown to be significantly elevated in db/db
fibroblasts in comparison to Het fibroblasts (Figure 3.4). Upon glycated albumin (AGEBSA) treatment, db/db fibroblasts did not show a significant increase in Rap1a protein
expression over that of Control (untreated) fibroblasts. This finding suggests RAGE
activation does not significantly change Rap1a expression levels. Next, Rap1a expression
was silenced using siRNA specific for Rap1a. siRNA treatments significantly decreased
Rap1a protein expression by 50-60% in both db/db and Het fibroblasts, and once again,
AGE-BSA treatment did not alter Rap1a expression. These data demonstrated Rap1a
protein expression was increased in diabetic fibroblasts, and a loss of Rap1a expression
restored diabetic Rap1a levels to near those of non-diabetic cells.
To further determine the activity of Rap1a in a diabetic mouse model a gain-offunction study was performed using the EPAC agonist 8-(4-Chlorophenylthio)-2’-Omethyladensosine 3’, 5’ cyclic monophosphate monosodium hydrate, otherwise referred to
as either 8-CPT-2Me-cAMP or 8-CPT. 8-CPT is an analog of cAMP that activates EPAC
when it dissociates GDP. 8-CPT is strongly selective for EPAC over alternative Rap1a
agonists, such as cAMP-activated kinase PKA (Yang, H., 2016). In these experiments,
Rap1a protein expression levels were significantly increased in diabetic fibroblasts treated
with 8-CPT and RAGE activation by AGE-BSA did not significantly elevate Rap1a
expression over that of Control (untreated) samples, as previously demonstrated.
Additionally, 8-CPT treated diabetic fibroblasts in Figure 3.5 had a noticeable increase in
Rap1a protein expression; however, 8-CPT did not elevate Rap1a expression over that
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Figure 3.4. Rap1a protein expression levels were significantly decreased with Rap1a
siRNA treatment in diabetic fibroblasts. Glycated albumin (AGE-BSA) treatment in db/db
fibroblasts did not show a significant increase in Rap1a protein expression over that of
Control (untreated) db/db fibroblasts, suggesting RAGE activation does not significantly
alter Rap1a expression levels. Rap1a expression was silenced using Rap1a siRNA, and
Rap1a protein expression was significantly decreased by 50-60% in both db/db and Het
treated fibroblasts compared to untreated Control samples. AGE-BSA treatment did not
change Rap1a protein expression. #p<0.05 db/db vs Comparable Het Group. Data
represents an n-value of 2-3 separate isolations with 3-4 mice per isolation. Het graph bars
were superimposed over db/db graph bars.
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Figure 3.5. Rap1a protein expression levels were significantly elevated with 8-CPT
treatment in diabetic fibroblasts. Rap1a protein expression levels were significantly
increased in diabetic fibroblasts and RAGE activation by AGE-BSA did not change Rap1a
protein expression over that of Control (untreated) samples. There were noticeable
increases in 8-CPT treated diabetic fibroblasts; however, 8-CPT did not elevate Rap1a
expression over that of Control (untreated) samples. #p<0.05 db/db vs Comparable Het
Group. Data represents an n-value of 2-3 separate isolations with 3-4 mice per isolation.
Het graph bars were superimposed over db/db graph bars.
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of Control (untreated) samples. Activating RAGE did not appear to significantly effect
Rap1a protein expression.
Collectively, the loss-of-function and gain-of-function studies demonstrated a
potential role for Rap1a in diabetes. Rap1a GTPase is a molecule involved in multiple
cascades and is responsible for potentiation of downstream signaling outcomes. Cascades
often overlap at key signaling hubs, such as the protein kinases and ERKs. Therefore, our
next step was to target key proteins within the AGE-RAGE cascade to determine if Rap1a
had a role in known signaling outcomes responsible for diabetic complications. PKC- ζ and
ERK1/2 were chosen due to their elevated activation levels and significant roles in the
AGE-RAGE signaling cascade in type II diabetic mellitus. Again, Rap1a siRNA was used
in a series of loss-of-function studies and 8-CPT was used in series of gain-of-function
studies to probe the role Rap1a plays in phosphorylation of PKC-ζ and ERK1/2 in the
AGE-RAGE signaling cascade.
In these experiments, PKC-ζ phosphorylation levels were significantly elevated in
the db/db Control and db/db AGE-treated samples over that observed in Het isolated
cardiac fibroblasts (Figure 3.6). Thus, demonstrating in db/db groups, AGE-RAGE
pathways have increased PKC-ζ phosphorylation levels that lead to further biological
outputs. Rap1a siRNA treatment was then used and phosphorylation levels of PKC-ζ were
measured by western blot analysis. We observed that phospho-PKC-ζ levels were
decreased in Rap1a-siRNA treated diabetic fibroblasts. Rap1a siRNA treatment returned
phosphorylation levels to that of a non-diabetic Het cell type. For gain-of-function study,
8-CPT, the EPAC agonist was used to increase Rap1a activity. These studies demonstrated
a significant increase in phosphorylation levels of PKC-ζ in diabetic
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Figure 3.6. Phospho-PKC-ζ (pPKC-ζ) protein expression levels were significantly
decreased under Rap1a siRNA treatment in diabetic fibroblasts. Phospho-PKC-ζ protein
expression levels were increased in diabetic fibroblasts and significantly increased RAGE
activation by AGEs over that of Control (untreated) samples. Phospho-PKC-ζ protein
expression levels were returned to nondiabetic Het levels upon treatment with Rap1a
siRNA treatment. pPKC-ζ protein expression levels were normalized to total PKC-ζ
protein. #p<0.05 db/db vs Comparable Het Group. Data represents an n-value of 2-3
separate isolations with 3-4 mice per isolation. Het graph bars were superimposed over
db/db graph bars.
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Figure 3.7. Phospho-PKC-ζ (pPKC-ζ) protein expression levels were increased with 8CPT treatment in diabetic fibroblasts. Phospho-PKC-ζ protein expression levels were
significantly increased in diabetic fibroblasts and RAGE activation by AGE-BSA did not
change Phospho-PKC-ζ protein expression over that of Control (untreated) samples. There
were noticeable increases 8-CPT treated diabetic fibroblasts; however, 8-CPT did not
elevate Phospho-PKC-ζ expression over that of Control (untreated) samples. pPKC-ζ
protein expression levels were normalized to total PKC-ζ protein. #p<0.05 db/db vs
Comparable Het Group. Data represents an n-value of 2-3 separate isolations with 3-4 mice
per isolation. Het graph bars were superimposed over db/db graph bars.
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fibroblasts as seen in Figure 3.7. EPAC agonist did little to change non-diabetic levels in
isolated cardiac fibroblasts.
Phospho-ERK1/2 levels were also analyzed and were found to be significantly
increased in db/db and AGE treated db/db cells as compared to Het Control cells. ERK1/2
has been shown to be located downstream from PKC-ζ in the AGE-RAGE signaling
cascade, and consequently ERK1/2 phosphorylation levels were elevated upon RAGE
stimulation (Yu, L., et al., 2013). These results also complement the phospho-PKC-ζ results
previously shown in Figure 3.6 and Figure 3.7, respectively, in that, the AGE-RAGE
signaling was potentiated further downstream when the cascade was activated.
Additionally, as before there was a return to near normal (Het Untreated) levels in db/db
cells treated with Rap1a siRNA, Figure 3.8. With EPAC Agonist, these data reflected
similar findings as observed in gain-of-function treatments that can be seen in Figure 3.9.
These findings demonstrated a role for Rap1a as a potential activator for key signaling hubs
in the AGE-RAGE signaling cascade.
The same experimental design was used to determine known outcomes of the
signaling cascade, particularly α-SMA and RAGE expression. These outcomes were
chosen as they directly reflect activation of AGE-RAGE signaling cascade. Increased
phosphorylation levels in both PKC-ζ and ERK1/2 translated to elevated protein expression
from α-SMA and RAGE downstream markers. α-SMA and RAGE protein levels were
quantitated by western blot analysis and were found to be significantly elevated in db/db
and in db/db-AGE-BSA treated db/db cells as compared to Het fibroblasts (Figure 3.10
and Figure 3.11, respectively). Administering Rap1a siRNA complemented the phosphoPKC-ζ and phospho-ERK1/2 results as previously
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Figure 3.8. Phospho-ERK1/2 (pERK1/2) protein expression levels were significantly
decreased with Rap1a siRNA in diabetic fibroblasts. Phospho-ERK1/2 protein expression
levels were increased in diabetic fibroblasts and significantly increased RAGE activation
by AGEs over that of Control (untreated) samples. Phospho-ERK1/2protein expression
levels were returned to non-diabetic Het levels upon treatment with Rap1a siRNA
treatment. pERK1/2 protein expression levels were normalized to total ERK1/2 protein.
#p<0.05 db/db vs Comparable Het Group. Data represents an n-value of 2-3 separate
isolations with 3-4 mice per isolation. Het graph bars were superimposed over db/db graph
bars.
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Figure 3.9. Phospho-ERK1/2 (pERK1/2) protein expression levels were not elevated with
8-CPT treatment in diabetic fibroblasts. Phospho-ERK1/2 protein expression levels were
significantly increased in diabetic fibroblasts and RAGE activation by AGE-BSA did not
change over that of Control (untreated) samples. There were noticeable increases 8-CPT
treated diabetic fibroblasts; however, 8-CPT did not elevate Phospho- ERK1/2 expression
over that of Control (untreated) samples. pERK1/2 protein expression levels were
normalized to total ERK1/2 protein. #p<0.05 db/db vs Comparable Het Group. Data
represents an n-value of 2-3 separate isolations with 3-4 mice per isolation. Het graph bars
were superimposed over db/db graph bars
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Figure 3.10. α-Smooth Muscle Actin (α-SMA) protein expression levels were significantly
decreased with Rap1a siRNA in diabetic fibroblasts. α-SMA protein expression levels were
increased in diabetic fibroblasts and significantly increased RAGE activation by AGEs
over that of Control (untreated) samples. α-SMA protein expression levels were returned
to non-diabetic Het levels upon treatment with Rap1a siRNA treatment. #p<0.05 db/db vs
Comparable Het Group. Data represents an n-value of 2-3 separate isolations with 3-4 mice
per isolation. Het graph bars were superimposed over db/db graph bars.

64

Figure 3.11. RAGE protein expression levels were significantly increased with 8-CPT
treatment in diabetic fibroblasts. RAGE protein expression levels were significantly
increased in diabetic fibroblasts and RAGE activation by AGE-BSA did not change. RAGE
protein expression over that of Control (untreated) samples. There were noticeable
increases 8-CPT treated diabetic fibroblasts; however, 8-CPT did not elevate PhosphoPKC-ζ expression over that of Control (untreated) samples. #p<0.05 db/db vs Comparable
Het Group. Data represents an n-value of 2-3 separate isolations with 3-4 mice per
isolation. Het graph bars were superimposed over db/db graph bars
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shown. In that, α-SMA protein expression was decreased when siRNA is used (Figure
3.10). EPAC Agonist elevated RAGE protein expression (Figures 3.11). Collectively, these
data demonstrated Rap1a intersects the AGE-RAGE signaling cascade. Changes in Rap1a
expression and activation directly impacted AGE-RAGE signaling proteins as well as
signaling outcomes. Our next step was to determine where Rap1a intersects the AGERAGE signaling components.
Specific secondary pharmacological agents were used to block either PKC-ζ
phosphorylation using PKC-ζ Pseudosubstrate (PS) or UO126 to block ERK1/2
phosphorylation. The goal of these studies were to 1) determine location in which Rap1a
intersects the AGE-RAGE cascade and 2) determine if AGE-RAGE signaling cascade
components and outcomes are altered when Rap1a siRNA or EPAC agonist therapies are
combined with PS or UO126 treatments. For these studies, cardiac fibroblasts were isolated
from db/db and Het mouse hearts. Once cells were ready to treat, pharmacological
inhibitors of PKC-ζ (PS) or ERK1/2 (UO126) were simultaneously applied with that for
loss-of-function (Rap1a siRNA) or gain-of-function (8-CPT). After cells were harvested,
western blot analysis was performed to probe for previously investigated markers, such as
Rap1a, phospho-PKC-ζ, phospho-ERK1/2, and α-SMA. For this series of studies, genotype
controls were set at 1.0 Fold of their own untreated controls to estimate changes within Het
and db/db fibroblasts independently.
Rap1a expression followed similar trends as documented earlier, in that db/db
AGE-treated cells had higher protein levels.
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Figure 3.12. Rap1a protein expression in specific inhibitor studies. Rap1a protein
expression levels significantly increased with RAGE activation by AGEs over that of
Control (untreated) db/db samples. Rap1a protein expression levels were returned to near
or below non-diabetic Het levels upon treatment with phospho-PKC-ζ inhibitor PKC-ζ
Pseudosubstrate (PS) and Rap1a siRNA treatment. Blocking ERK1/2 phosphorylation with
UO126 slightly reduced Rap1a expression levels but not to the extent as PKC-ζ PS or
Rap1a siRNA. *p<0.05 vs. Genotype Control. Data represents an n-value of 3-4 separate
isolations with 3-4 mice per isolation. Genotype controls were set at 1.0 Fold to estimate
changes within Het and db/db fibroblast groups independently.
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Figure 3.13. phospho-PKC-ζ (pPKC-Z) protein expression in specific inhibitor studies.
Rap1a protein expression levels significantly increased with RAGE activation by AGEs
over that of Control (untreated) db/db samples. Phospho-PKC-ζ protein expression levels
were returned to near or below non-diabetic Het levels upon treatment with phospho-PKCζ inhibitor PKC-ζ Pseudosubstrate (PS) and Rap1a siRNA treatment. Blocking ERK1/2
phosphorylation with UO126 did not alter phospho-PKC-ζ expression levels. pPKC-ζ
protein expression levels were normalized to total PKC-ζ protein. *p<0.05 vs. Genotype
Control. Data represents an n-value of 3-4 separate isolations with 3-4 mice per isolation.
Genotype controls were set at 1.0 Fold to estimate changes within Het and db/db fibroblast
groups independently.
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Figure 3.14. phospho-ERK1/2 (pERK) protein expression in specific inhibitor studies.
Rap1a protein expression levels significantly increased with RAGE activation by AGEs
over that of Control (untreated) db/db samples. Phospho-ERK1/2 protein expression levels
were returned to near or below non-diabetic Het levels upon treatment with phospho-PKCζ inhibitor PKC-ζ Pseudosubstrate (PS) and Rap1a siRNA treatment. Blocking ERK1/2
phosphorylation with UO126 dramatically decreased phospho-ERK1/2 expression levels.
pERK1/2 protein expression levels were normalized to total ERK1/2 protein. *p<0.05 vs.
Genotype Control. Data represents an n-value of 3-4 separate isolations with 3-4 mice per
isolation. Genotype controls were set at 1.0 Fold to estimate changes within Het and db/db
fibroblast groups independently.
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Figure 3.15. α-Smooth Muscle Actin (SMA) protein expression in specific inhibitor
studies. Rap1a protein expression levels significantly increased with RAGE activation by
AGEs over that of Control (untreated) db/db samples. α-SMA protein expression levels
were returned to near or below non-diabetic Het levels upon treatment with phospho-PKCζ inhibitor PKC-ζ Pseudosubstrate (PS), UO126, and Rap1a siRNA treatment. *p<0.05 vs.
Genotype Control. Data represents an n-value of 3-4 separate isolations with 3-4 mice per
isolation. Genotype controls were set at 1.0 Fold to estimate changes within Het and db/db
fibroblast groups independently.
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Further studies were performed to compare differences in phospho-PKC-ζ and phosphoERK1/2 to determine crosstalk between the two signaling systems.
Previous studies showed phospho-PKC-ζ protein expression is elevated in db/db
AGE-treated cells. These findings were mirrored in Figure 3.13. UO126 treated db/db
samples had higher phospho-PKC-ζ protein levels as one would expect. PKC-ζ PS
treatment returned activation levels to that of Rap1a siRNA samples. Phospho-ERK1/2
expression levels were elevated in AGE-treated db/db samples, Figure 3.14. UO126 treated
db/db fibroblasts showed decreased ERK1/2 activation; however, PKC-ζ PS and Rap1a
siRNA treated db/db cells had less of a dramatic decrease in phospho-ERK1/2. These
findings suggest experimentally Rap1a is more than likely intersecting the AGE-RAGE
cascade at PKC-ζ due to similarities observed when fibroblasts were treated with PKC-ζ
and Rap1a siRNA. ERK1/2 represents a common downstream player for a number of
signaling cascades, which may explain the variability observed in PKC-ζ PS and Rap1a
siRNA treated db/db cells. In addition, PKC-ζ may be a more viable candidate option due
to cellular location and proximity to Rap1a molecules.
For these series of pharmacological studies, a physiological output was measured
to determine effectiveness of inhibitory treatments. α-SMA protein expression was used to
test responsiveness of cascade and downstream marker for alterations in AGE-RAGE
signaling. In Figure 3.15 PKC-ζ PS, UO126, and Rap1a siRNA treatment resulted in
significant decreases in α-SMA protein expression, and AGE treatments increasing α-SMA
expression. The in vitro studies defined a role for Rap1a in the diabetic fibroblasts. Our
next step was to define a role for Rap1a in vivo in diabetic mice.
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A double knockout mouse model was generated by crossing db/db mouse line with
that of Rap1a knockout mice. Complications arose when db/dbRap-/- were produced. At 3-4
weeks of age, the double knockout mouse died unexpected. Loss of these mice were
correlated with changes in glucose levels. When db/dbRap-/- mice began gaining weight and
experiencing intermittent hyperglycemia, morbidity/mortality rates increased and resulted
in an alternative approach to achieve diabetes in the Rap1a knockout strain. To avoid
morbidity and mortality observed in db/dbRap-/-, Rap1a heterozygous mice (Rap1a+/-) were
fed a 60% high fat (HF) diet for 12 weeks starting at 4 weeks of age, and mice were
sacrificed at 16 weeks of age. 16 weeks of age is the same age at which animals were
sacrificed in previous studies. This diet has been demonstrated to cause onset of clinical
diabetic conditions, such as hyperglycemia and obesity (Skovsø, S., 2014) While neither
C-reactive peptide nor insulin levels were measured, the disease state described will be
referred to as prediabetes/diabetes from this point forward. The following data sets
demonstrate the physiological parameters generated from high fat diet consumption in
Rap1a wildtype (Rap1a+/+) and Rap1a heterozygous (Rap1a+/-) mice.
Body weights were taken to determine obesity, a marker for prediabetes/diabetes,
between HF diet fed Rap1a+/+ and Rap1a+/- mice. In Figure 3.16, body weights were
significantly increased in both genotypes fed the HF diet. Figure 3.17 indicates changes in
heart weight. As a result of the HF diet, there were significant increases in heart weight in
both the Rap1a+/+ and Rap1a+/- HF diet mice. Heart weight to body weight ratios were
then calculated to determine if significant metabolic changes, such as hypertension,
occurred due to the HF diet. In Figure 3.18, there were significant decreases in both
Rap1a+/+ and Rap1a+/- HF diet groups. Decreases in heart weight to body weight ratios
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are indicative of increased body size or obesity in the absence of cardiac hypertrophy. This
observation is typical for rodent models of metabolic disease, as rodents are generally
protected against increased afterload caused by hypertension. Lastly, blood glucose
measurements were taken after an overnight fast. Blood glucose levels were increased in
both HF diet groups, Figure 3.19. These findings strongly indicate HF diet mouse groups
were in a prediabetic/diabetic pathology state. As such, changes in Rap1a and AGE-RAGE
signaling outcomes should be evident.
Rap1a levels were measured to determine changes in protein expression. In Figure
3.20, Rap1a levels were significantly increased in HF diet Rap1a+/+ mice in comparison
to normal diet fed Rap1a+/+ mice. Additionally, Rap1a+/- normal diet and HF diet showed
slightly lower levels of Rap1a protein expression. These findings indicated that the partial
presence of Rap1a allele was sufficient to reduce increases in Rap1a expression in a
prediabetic/diabetic condition. Therefore, Rap1a levels were reduced to that of normal fed,
non-prediabetic/diabetic mice. From previous in vitro studies, fibroblast specific AGERAGE signaling outcomes should be minimized in whole heart protein samples.
In Figure 3.21, α-SMA protein expression was increased in HF diet Rap1a+/+
hearts compared to normal fed groups and the Rap1a+/- HF diet group. α-SMA is a marker
for fibroblast to myofibroblast differentiation. Thus, changes in α-SMA expression as a
result of prediabetes/diabetes are similar changes observed in isolated diabetic cardiac
fibroblasts, Figure 3.21. Additionally, RAGE expression was also elevated increased in
Rap1a+/+ HF fed mice as compared to normal fed groups and the Rap1a+/- HF diet group,
Figure 3.22.
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Figure 3.16. Body weights were significantly elevated in high-fat (HF) diet animals
compared to normal diet fed animals. This indicates obesity in these groups of mice.
*p<0.05 vs. Wild type (WT) Normal Diet. #p<0.05 Rap+/- HF vs. Rap1a Normal diet. Data
represents an n-value of 2-3 mice per group.
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Figure 3.17. Heart weights were significantly elevated in high-fat (HF) diet animals
compared to normal diet fed animals. *p<0.05 vs. Wild type (WT) Normal Diet. #p<0.05
Rap+/- HF vs. Rap1a Normal diet. Data represents an n-value of 2-3 mice per group.
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Figure 3.18. Heart weight to body weight ratios were significantly decreased in high-fat
(HF) diet animals compared to normal diet fed animals. This is indicative of obesity in the
absence of cardiac hypertrophy. *p<0.05 vs. Wild type (WT) Normal Diet. #p<0.05 Rap+/HF vs. Rap1a Normal diet. Data represents an n-value of 2-3 mice per group.
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Figure 3.19. Blood glucose levels were significantly increased in high-fat (HF) diet animals
compared to normal diet fed animals. This is indicative of hyperglycemia. *p<0.05 vs.
Wild type (WT) Normal Diet. #p<0.05 Rap+/- HF vs. Rap1a Normal diet. Data represents
an n-value of 2-3 mice per group.
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Figure 3.20. Rap1a protein expression was not significantly changed in high-fat fed (HF)
Rap1a heterozygous (Rap1a+/-) as that in HF Wild type (WT; Rap1a+/+). Rap1a protein
expression increased in high-fat fed (HF) Wild type (WT; Rap1a+/+) mice, while Rap1a
heterozygous (Rap1a+/-), had only slight increases above that of Rap1a+/+ and Rap1a+/-.
p<0.05 Rap+/- HF vs. Rap1a Normal diet. Data represents an n-value of 2-3 mice per
group.
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Figure 3.21. α-Smooth Muscle Actin (α-SMA) protein was not significantly changed in
high-fat fed (HF) Rap1a heterozygous (Rap1a+/-) as that in HF Wild type (WT; Rap1a+/+).
α-SMA protein expression was significantly increased in high-fat (HF) fed Wild type (WT;
Rap1a+/+) mice, while Rap1a heterozygous (Rap1a+/-), had only slight increases above
that of Rap1a+/+ and Rap1a+/-. p<0.05 Rap+/- HF vs. Rap1a Normal diet. Data represents
an n-value of 2-3 mice per group.
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Figure 3.22. RAGE protein was not significantly changed in high-fat fed (HF) Rap1a
heterozygous (Rap1a+/-) as that in HF Wild type (WT; Rap1a+/+). RAGE protein
expression was significantly increased in high-fat (HF) Wild type (WT; Rap1a+/+) mice,
while Rap1a heterozygous (Rap1a+/-), had only slight increases above that of Rap1a+/+
and Rap1a+/-. p<0.05 Rap+/- HF vs. Rap1a Normal diet. Data represents an n-value of 23 mice per group.

80

Figure 3.23. Percentage change in Rap1a protein expression with siRNA treatment. siRNA
treatment decreased the expression of Rap1a protein by 36% in Het fibroblast groups and
38% in db/db fibroblast groups. *p<0.05 vs. Genotype Control. Data represents an n-value
of 2-3 separate isolations with 3-4 mice per isolation. Genotype controls were set at 1.0
Fold to estimate changes within Het and db/db fibroblast groups independently.
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Interestingly, the in vivo HF diet model demonstrated a potential feedback mechanism to
regulate RAGE expression not observed in the in vitro model. Phospho-PKC-ζ and
phospho-ERK1/2 levels (not shown) were measured; however, results were variable and
inconsistent and did not reflect changes observed in the cell culture model system. Western
blot analysis for HF diet experiments were conducted using ventricular protein
preparations. Using a mixed cell population whereby cardiac myocytes are the predominant
cell type could explain differences in AGE-RAGE signaling components.
The presented data demonstrates a link exists between Rap1a and the AGE-RAGE
signaling cascade. The performed studies determined that the downstream effects of AGERAGE signaling in type II diabetes mellitus was potentiated or more specifically
exacerbated by Rap1a GTPase signaling. Changes in Rap1a expression through either gainof-function or loss-of-function experiments resulted in comparable alterations in protein
expression in defined AGE-RAGE cascade outcomes, such as α-SMA and RAGE. In
addition, AGE-RAGE signal transduction molecules, such as PKC- ζ and ERK1/2, had
similar phosphorylation responses upon Rap1a stimulation or Rap1a knockdown
experiments. Inhibiting PKC-ζ phosphorylation by administering PKC-ζ PS in vitro halted
downstream progression of the Rap1a-AGE-RAGE signaling cascade. Thus, from this data
we have determined Rap1a exerts its effects on the AGE-RAGE cascade through crosstalk
with PKC-ζ. Furthermore, inhibiting ERK1/2 phosphorylation by administering UO126 in
vitro slightly decreased stimulation of the Rap1a-AGE-RAGE signaling cascade crosstalk.
Finally, feeding both Rap1a wild type and heterozygous mice a HF diet resulted in
prediabetes/diabetes condition and a subsequent increase in Rap1a protein levels in
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Rap1a+/+ mice. Elevated Rap1a levels further promoted AGE-RAGE signaling which was
documented by increased α-SMA and RAGE protein expression. Rap1a+/- mice appeared
to be protected from AGE-RAGE outcomes despite prediabetes/diabetes condition. Thus,
suggesting Rap1a may play a contributing role in promoting diabetic complications. While
further confirmation studies need to be performed, these studies are the first of its kind to
provide Rap1a as a unique target for therapeutic strategies aimed at reducing chronic
hyperglycemia-mediated ECM production and accumulation in diabetic patients.
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CHAPTER V
DISCUSSION
The purpose of this project was to investigate a Rap1a-dependent molecular link
between type II diabetic mellitus and cardiac fibrosis. We proposed that under type II
diabetic mellitus conditions, hyperglycemia was the driving factor to increase the rate of
AGE formation. In particular, AGEs bind to their receptors, RAGEs, to initiate a
downstream signaling cascade, resulting in numerous diabetic complications, such as
cardiac fibrosis.
Our preliminary experimental results showed that the expression levels of AGERAGE signaling pathway markers, such as RAGE, α-SMA, and collagen, were increased
under type II diabetic conditions as compared to non-diabetic conditions. With Rap1a
silencing RNA treatment, these markers were returned to non-diabetic levels. From these
findings, we sought to determine whether Rap1a plays a key role in the AGE-RAGE
cascade. Additional preliminary data, Rap1a expression was significantly elevated in type
II diabetic hearts. Additionally, knocking out Rap1a using a genetic model resulted in a
loss of cardiac interstitial collagen in an allele dependent manner. In order to test this
phenomenon, we used a three-way approach to determine the role of Rap1a in the AGERAGE cascade. Firstly, Rap1a siRNA treatment was used to knockdown Rap1a expression
for a loss-of-function approach. Secondly, in additional separate studies, an EPAC agonist
(8-CPT) was used to increase Rap1a expression for a gain-of-function. For both studies,
we observed that AGE-RAGE signaling pathway mediators such as p-PKC-ζ and p84

ERK1/2 were affected as well as known outputs of the AGE-RAGE signaling cascade (i.e.,
RAGE and α-SMA protein expression levels). Lastly, a whole animal approach was used
to experimentally induce diabetes through a high fat diet to determine if Rap1a was a player
in the AGE-RAGE cascade in vivo.
In Specific Aim 1, a loss-of-function approach was used to decrease Rap1a protein
expression via Rap1a siRNA. After 48 hours post siRNA treatment targeting Rap1a, we
found that siRNA treatment decreased the expression of Rap1a protein by 36% in nondiabetic and 38% in diabetic cells, respectively. Rap1a knockdown significantly decreased
protein markers and physiological outcomes of the AGE-RAGE pathway, such as PKC-ζ,
ERK1/2, RAGE and α-SMA. Interestingly, in the diabetic (db/db) fibroblasts protein
expression levels were returned back to non-diabetic Het levels. For example, based on the
loss-of-function study, we found that after the treatment with siRNA targeting Rap1a, the
protein expression level of α-smooth muscle actin (α-SMA), a biomarker for fibroblasts
differentiation, was returned back to a non-diabetic levels. This finding demonstrated that
knocking down Rap1a protein expression AGE-RAGE mediated outcomes related to
diabetes was downregulated. Thus, providing evidence that Rap1a expression and activity
intersects the AGE-RAGE signaling cascade under type II diabetic conditions. These
hierarchal signaling studies will be discussed in more detail later.
For Specific Aim 1, we also wanted to define the role of the key molecular players
involved in this signaling pathway, which were PKC-ζ and ERK1/2. To address this
question, specific antagonist treatments were used to inhibit PKC-ζ phosphorylation (PKCζ pseudosubstrate (PS)) and ERK1/2 phosphorylation (UO126). These studies allowed us
to determine a possible point of intersection for Rap1a within the AGE-RAGE cascade.
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PKC-ζ and ERK1/2 have been demonstrated to heavily participate in the AGE/RAGE
pathway under type II diabetic conditions, and changes in the expression level of either
PKC-ζ or ERK1/2 will influence the outcomes of AGE-RAGE pathway. Therefore,
decreasing Rap1a activity would alter the phosphorylation levels of PKC-ζ and ERK1/2,
either jointly or independently depending on the location Rap1a intersects the AGE-RAGE
pathway. Experimental data showed that the phosphorylation levels of both PKC-ζ and
ERK1/2 were decreased with Rap1a siRNA treatment under type II diabetic conditions.
Together with the finding that both PKC-ζ and ERK1/2 are involved in AGE-RAGE
signaling pathway under type II diabetic condition, we can say that it is very likely that an
interactive relationship exists with Rap1a. Furthermore, our results provided us with
evidence that Rap1a acts as an upstream player where PKC-ζ and ERK1/2 are downstream
in the AGE-RAGE signaling pathway under type II diabetic conditions. These findings
also suggest the point of intersection is at PKC-ζ based on significant downregulation of
phosphorylation observed when cells were treated with Rap1a siRNA. pERK
phosphorylation levels varied when cells underwent similar treatments.
Using an alternative approach in Specific Aim 2, we conducted a gain-of-function
study by using 8-CPT, which acts as agonist for EPAC, to stimulate Rap1a activity and
expression. By altering the expression and activity levels of Rap1a, the outcomes and signal
mediators of the AGE-RAGE signaling cascade should be consequently altered as observed
in Specific Aim 1. We demonstrated that phosphorylation levels of PKC-ζ and ERK1/2, as
well as RAGE expression levels were increased by the addition of 8-CPT treatment under
type II diabetic conditions. More specifically, the gain-of-function approach increased the
expression levels of Rap1a protein resulting subsequent increases in the levels of ERK1/2
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and PKC- ζ phosphorylation. This elevation in signaling modulators led to elevated
expression levels of α-SMA and RAGE under type II diabetic conditions. In these
experiments, increasing Rap1a expression enhanced the outcomes of AGE-RAGE
signaling pathway. To further determine if PKC-ζ and ERK1/2 are sites of intersection in
AGE-RAGE signaling cascade for Rap1a, we used our findings from Specific Aim 1 to
design further experiments to determine if Rap1a was acting as an upstream mediator of
PKC- ζ and/or ERK1/2 in the AGE-RAGE signaling pathway under type II diabetic
conditions.
In order to piece together the AGE-RAGE cascade hierarchy and how changes in
Rap1a activity may affect signaling components, we inhibited PKC-ζ phosphorylation
using PKC-ζ pseudosubstrate (PS), ERK1/2 phosphorylation using UO126, and silenced
Rap1a expression in the cardiac fibroblasts in combinatorial treatments as well as
independently. This experimental design would allow us to determine if Rap1a integration
occurs upstream or downstream from PKC-ζ or ERK1/2. The presented results
demonstrated that Rap1a siRNA treatment decreased phospho-PKC-ζ more so than
phospho-ERK1/2. PKC-ζ inhibition only interrupted the expression level of ERK1/2 but
not vice versa. Neither the PKC-ζ inhibition nor the ERK1/2 inhibition influenced the
expression levels of Rap1a. Therefore, we can say that PKC-ζ signaling hub is a possible
site of intersection of Rap1a with the AGE-RAGE signaling pathway under type II diabetic
conditions. We also demonstrated that Rap1a acts as an upstream molecule for PKC-ζ.
Moreover, when we inhibited the activity of ERK1/2 with its specific inhibitor, UO126,
our results demonstrated that decreasing the expression level of ERK1/2 returned α-SMA,
expression level back to non-diabetic level. These findings provided us evidence that
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ERK1/2 was positioned lower within AGE-RAGE signaling cascade under type II diabetic
conditions and may have less of an influence on the intersection of Rap1a with the AGERAGE cascade. Specific inhibitors for PKC- ζ and ERK1/2 proved to have little to no
influence on the expression levels of Rap1a. Our specific inhibitor treatment using a gainof-function approach demonstrated that Rap1a acts as an upstream mediator for PKC-ζ and
changes in Rap1a expression altered the activity levels of PKC-ζ directly and activity levels
of ERK1/2 indirectly.
In Specific Aims 1 and 2, we demonstrated that Rap1a plays a key role in AGERAGE signaling cascades under type II diabetic condition. Furthermore, Rap1a inhibition
decreases the phosphorylation levels of both PKC-ζ and ERK1/2. Conversely, PKC-ζ PS
treatment and UO126 treatment do not alter the expression levels of Rap1a. We also
demonstrated that activating Rap1a resulted in stimulating downstream mediators, such as
pPKC-ζ and pERK1/2, to increase the protein expression level of physiological outcomes
of the AGE-RAGE signaling cascade under type II diabetic conditions. These findings
further indicated a role for Rap1a in the AGE-RAGE signaling cascade under type II
diabetic conditions, and the loss-of-function and gain-of-studies showed that AGE-RAGE
signaling cascade is dependent on Rap1a GTPase in type II diabetic conditions.
In Specific Aim 3, an in vivo approach was performed to determine if changes in
Rap1a expression mediated AGE-RAGE signaling outcomes in the heart. Under
pathological conditions, type II diabetic hearts have increased collagen expression, and
consequently, increased collagen deposition and fibrosis are the resulting outcomes. As
mentioned earlier, increases in cardiac fibrosis will detrimentally alter cardiac function.
Previous studies from our lab demonstrated that collagen volumes were reduced based
88

upon Rap1a allele penetrance. In fact, the significance of these findings established the
premise for this dissertation. Therefore, we wanted to determine if decreasing either the
presence or activity of Rap1a within the heart could alter AGE-RAGE signaling outcomes.
Initially, we proposed to cross the existing Rap1a knock mice strain (Rap1a-/-) into the
db/db diabetic mice strain to develop a diabetic Rap1a knockout mice model (db/dbRap1a/-

). Attempts to cross Rap1a knockout mice into the db/db diabetic strain resulted in a high

morbidity/mortality rate for the db/dbRap1a-/- mice. For this study aim, we use a 60% high
fat (HF) diet to feed Rap1a wild type (Rap1a+/+) mice and heterozygous (Rap1a+/-) mice
in order to develop a similar outcome that a double knock out mice model might provide.
Additionally, Rap1a+/- mice were used instead of Rap1a-/- mice to ensure survival of the
animals in case Rap1a knockout animals were more susceptible to metabolic conditions
experienced with type II diabetic mellitus.
Our results from Specific Aim 3 demonstrated, that with a high fat diet, the mice
developed type II diabetic characteristics, such as increased body weights and increased
blood glucose levels. These mice effectively developed prediabetic to diabetic symptoms
commonly displayed by humans. Additionally, the in vivo study showed that by deleting
only one allele of the Rap1a gene (Rap1a+/-), the expression levels of AGE-RAGE
signaling mediators, which included Rap1a, RAGE and α-SMA protein expression,
returned back to a non-diabetic expression level as compared with Rap1a+/+ HF fed mice,
which had a significantly increased expression levels of both RAGE protein and α-SMA
protein. These results demonstrated that by decreasing the expression level of Rap1a
protein, it would protect HF fed, pre-diabetic to diabetic mice from adverse AGE-RAGE
signaling outcomes, such as increased α-SMA and RAGE protein expression. These
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findings are significant in that long term complications, such as fibroblast differentiation,
fibrosis, and RAGE up-regulation, could be dampened. Therefore, our in vivo results
support the findings that by decreasing the expression levels of Rap1a, we are able to
effectively decrease the maladaptive outcomes of AGE-RAGE signaling which contribute
to cardiac fibrosis under type II diabetic mellitus.
Collectively, the data we provided defines a molecular link between AGE-RAGE
signaling cascade and Rap1a GTPase in the diabetic heart. We observe that both in vitro
and in vivo changes of Rap1a protein expression influenced the biological outcomes of
AGE-RAGE signaling pathway. Completion of this study has identified a new molecular
mechanism, which could prevent fibroblast differentiation and ECM remodeling in type II
diabetes mellitus. Also, we have provided a potential molecular therapy target, Rap1a, for
type II diabetic mellitus complications. Further studies must be performed in order to
confirm the conclusions presented herein. We believe that these findings are the first of its
kind to provide Rap1a, potentially, as a unique target for therapeutic strategies aimed at
reducing chronic hyperglycemia-mediated ECM production and accumulation as well as
fibroblast differentiation in the diabetic heart.
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CHAPTER VI
FUTURE DIRECTIONS
It has been demonstrated that the interaction between angiotensin II (ANGII) and
its G-protein coupled receptor (GPCR), the angiotensin type I receptor (AT1R), will
stimulate AGE-RAGE signaling pathway by up-regulating AGE formation and
accumulation as well as increase RAGE expression via a PKA-dependent manner
(Ramasamy, R., et al., 2011). To date, no inter-related molecules have been demonstrated
to potentiate this response. For these studies, our goal was to introduce Rap1a GTPase as
a potential linking molecule involved in joining these two disparate signaling pathways.
Studies have demonstrated that Rap1a protein is activated upon initiation of a GPCR-PKAindependent pathway (Zhi, W., 2006). EPAC-Rap1a stimulation, specifically EPAC-PKCRap1a, has been suggested to regulate the activation of cardiac myofibroblasts and ECM
accumulation under pro-fibrotic TGF-beta treatment (Fukami, K., et al., 2007). Combined
with our previous studies, we proposed that Rap1a protein might be involved in a PKAdependent AGE-RAGE signaling pathway.
Our data suggests that Rap1a protein is the potential target in type II diabetes
mediated fibrosis, and the deletion of Rap1a in mice module will result in the downregulation of long-term diabetic complications. Therefore, if we were able to systematically
knockout or knockdown the Rap1a gene and gene products, we can demonstrate that
outcomes, such as collagen production, myofibroblast differentiation, and RAGE
expression and activation, would be minimized to alleviate diabetic complications.
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Besides the systematically gene knocking out, using of the already known proteinprotein interaction networks databases to identify potential protein therapy target is one
approach for our next step drug design. However, this protein-protein interaction networks
have numerous false-positive entries. This causes difficulties in the low affinity protein
interaction inclusion and assessment. Moreover, most databases do not consider whether
or not the two proteins are expressed at the time and location, which leads to interpretation
problems during our potential protein target screening process (Tamás, K., et al., 2007).
Furthermore, experimental work would be performed to determine if a proteinprotein interaction exists between Rap1a and PKC-ζ or ERK1/2, as well as to identify
potential binding sites for this interaction. Determining the interaction would bring this
work closer to developing a therapeutic target for drug design. Having a pharmaceutical
agent available would allow patients to maintain a longer and better quality of life.
Ultimately, type II diabetic patients will succumb to the complications of the disease. Thus,
having an agent to reduce the impact of type II disease long term complications would
benefit diabetic patients tremendously. Therefore, the identification of these protein targets
will bring a clear potential direction for drug or therapy development in TIIDM
complications related clinical research.
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A.1 Genotyping result for leptin receptor

1kb DNA ladder was loaded as the right most lane. Lane with 135bp band (lower band)
only shows the result of knockout (db/db). Lane with 187bp band (upper band) only shows
the result of wild type (Db/Db). Lane with both 135bp and 187bp bands (lower and upper
bands) shows the result of heterozygotes (Db/db).
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A.2 Genotyping result for Rap1a

Lane with 1107bp band (lower band) only shows the result of knockout (Rap1a-/-). Lane
with 1358bp band (upper band) only shows the result of wild type (Rap1a+/+). Lane with
both 1107bp and 1358bp bands (lower and upper bands) shows the result of heterozygotes
(Rap1a+/-).
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